<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Aust N Z J Psychiatry</journal-id><journal-id journal-id-type="publisher-id">ianp</journal-id><journal-title-group><journal-title>The Australian and New Zealand Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0004-8674</issn><issn pub-type="epub">1440-1614</issn><publisher><publisher-name>Informa Healthcare</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21888608</article-id><article-id pub-id-type="pmc">3190838</article-id><article-id pub-id-type="doi">10.3109/00048674.2011.595686</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A consensus statement for safety monitoring guidelines of treatments for major depressive disorder</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dodd</surname><given-names>Seetal</given-names></name><role>Clinical Senior Lecturer; Senior Fellow</role><xref ref-type="aff" rid="au1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Malhi</surname><given-names>Gin S</given-names></name><role>Professor and Head</role><xref ref-type="aff" rid="au2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tiller</surname><given-names>John</given-names></name><role>Professor</role><xref ref-type="aff" rid="au3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schweitzer</surname><given-names>Isaac</given-names></name><role>Professor</role><xref ref-type="aff" rid="au3"/></contrib><contrib contrib-type="author"><name><surname>Hickie</surname><given-names>Ian</given-names></name><role>Executive Director</role><xref ref-type="aff" rid="au4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Khoo</surname><given-names>Jon Paul</given-names></name><role>Consultant Psychiatrist</role><xref ref-type="aff" rid="au5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bassett</surname><given-names>Darryl L</given-names></name><role>Adjunct Professor</role><xref ref-type="aff" rid="au6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lyndon</surname><given-names>Bill</given-names></name><role>Clinical Senior Lecturer</role><xref ref-type="aff" rid="au2"/></contrib><contrib contrib-type="author"><name><surname>Mitchell</surname><given-names>Philip B</given-names></name><role>Head</role><xref ref-type="aff" rid="au7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Parker</surname><given-names>Gordon</given-names></name><role>Scientia Professor</role><xref ref-type="aff" rid="au7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fitzgerald</surname><given-names>Paul B</given-names></name><role>Professor</role><xref ref-type="aff" rid="au8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Udina</surname><given-names>Marc</given-names></name><role>Psychiatrist</role><xref ref-type="aff" rid="au9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Ajeet</given-names></name><role>Consultant Psychiatrist &#x00026; Clinical Senior Lecturer</role><xref ref-type="aff" rid="au1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Moylan</surname><given-names>Steven</given-names></name><role>Clinical Lecturer</role><xref ref-type="aff" rid="au10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Giorlando</surname><given-names>Francesco</given-names></name><role>Psychiatry Registrar</role><xref ref-type="aff" rid="au3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Doughty</surname><given-names>Carolyn</given-names></name><role>Psychologist; Clinical Lecturer</role><xref ref-type="aff" rid="au11"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Davey</surname><given-names>Christopher G</given-names></name><role>Consultant Psychiatrist</role><xref ref-type="aff" rid="au12"><sup>12</sup></xref></contrib><contrib contrib-type="author"><name><surname>Theodoras</surname><given-names>Michael</given-names></name><role>Director</role><xref ref-type="aff" rid="au13"><sup>13</sup></xref></contrib><contrib contrib-type="author"><name><surname>Berk</surname><given-names>Michael</given-names></name><role>Professor</role><xref ref-type="aff" rid="au14"><sup>14</sup></xref></contrib><aff id="au1"><sup>1</sup>School of Medicine, Deakin University, Geelong, Victoria, Australia; Department of Psychiatry, University of Melbourne, Victoria, Australia</aff><aff id="au2"><sup>2</sup>Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia</aff><aff id="au3"><sup>3</sup>Department of Psychiatry, University of Melbourne, Victoria, Australia</aff><aff id="au4"><sup>4</sup>Brain and Mind Research Institute, University of Sydney, Sydney, New South Wales, Australia</aff><aff id="au5"><sup>5</sup>Toowong Specialist Clinic, Level 2/54 Jephson St, Toowong, Brisbane, Queensland, Australia</aff><aff id="au6"><sup>6</sup>School of Psychiatry and Clinical Neurosciences, University of Western Australia, Australia; School of Medicine, University of Notre Dame, Western Australia, Australia</aff><aff id="au7"><sup>7</sup>School of Psychiatry, University of New South Wales, Sydney, Australia; Black Dog Institute, Sydney, Australia</aff><aff id="au8"><sup>8</sup>Monash Alfred Psychiatry Research Centre, Alfred and Monash University School of Psychology and Psychiatry, Melbourne, Victoria, Australia</aff><aff id="au9"><sup>9</sup>Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biom&#x000e8;diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red de Salud Mental (CIBERSAM), Barcelona, Catalonia, Spain</aff><aff id="au10"><sup>10</sup>School of Medicine, Deakin University, Geelong, Victoria, Australia</aff><aff id="au11"><sup>11</sup>Child and Family Specialty Service, Canterbury District Health Board; Department of Public Health and General Practice, University of Otago, Christchurch, New Zealand</aff><aff id="au12"><sup>12</sup>Orygen Youth Health Research Centre, Parkville, Victoria, Australia</aff><aff id="au13"><sup>13</sup>Eating Disorders Program, New Farm Clinic, Brisbane, Queensland, Australia</aff><aff id="au14"><sup>14</sup>School of Medicine, Deakin University, Geelong, Victoria; Department of Psychiatry, University of Melbourne, Victoria; Mental Health Research Institute, Parkville, Victoria; Orygen Youth Health Research Centre, Parkville, Victoria, Australia</aff></contrib-group><pub-date pub-type="ppub"><month>9</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>03</day><month>9</month><year>2011</year></pub-date><volume>45</volume><issue>9</issue><fpage>712</fpage><lpage>725</lpage><permissions><copyright-statement>&#x000a9; 2011 The Royal Australian and New Zealand College of Psychiatrists</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf">Supplemental Terms and Conditions for iOpenAccess articles published in Informa Healthcare journals</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>This paper aims to present an overview of screening and safety considerations for the treatment of clinical depressive disorders and make recommendations for safety monitoring.</p></sec><sec><title>Method</title><p>Data were sourced by a literature search using MEDLINE and a manual search of scientific journals to identify relevant articles. Draft guidelines were prepared and serially revised in an iterative manner until all co-authors gave final approval of content.</p></sec><sec><title>Results</title><p>Screening and monitoring can detect medical causes of depression. Specific adverse effects associated with antidepressant treatments may be reduced or identified earlier by baseline screening and agent-specific monitoring after commencing treatment.</p></sec><sec><title>Conclusion</title><p>The adoption of safety monitoring guidelines when treating clinical depression is likely to improve overall physical health status and treatment outcome. It is important to implement these guidelines in the routine management of clinical depression.</p></sec></abstract></article-meta></front><body><p>Major depressive disorder (MDD) afflicts an estimated 16% to 20% of the population during their lifetime [<xref ref-type="bibr" rid="b1">1</xref>-<xref ref-type="bibr" rid="b3">3</xref>]. In Australia 3.1% of men and 5.1% of women are affected in any 12-month period [<xref ref-type="bibr" rid="b4">4</xref>]. Current treatments include pharmacological, psychological and physical therapies. Antidepressants are amongst the most commonly prescribed classes of drugs [<xref ref-type="bibr" rid="b5">5</xref>] and their use continues to grow [<xref ref-type="bibr" rid="b6">6</xref>]. Adverse outcomes are part of the landscape in prescribing medications and therefore management of safety issues need to be an integral part of practice.</p><p>The adverse effects of antidepressants vary between individual drugs and drug classes and have been extensively documented [<xref ref-type="bibr" rid="b7">7</xref>-<xref ref-type="bibr" rid="b9">9</xref>]. In general tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) are associated with more severe adverse effect profiles than the newer antidepressants. MAOIs interact with dietary tyramine necessitating patient counselling about dietary risks [<xref ref-type="bibr" rid="b10">10</xref>]. While there is substantial intra-variation in tolerability, MAOIs and TCAs retain an important place in the management of refractory depression [<xref ref-type="bibr" rid="b10">10</xref>] and the more putatively biological depressive disorders such as melancholia [<xref ref-type="bibr" rid="b11">11</xref>]. The selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and noradrenaline reuptake inhibitors (SNRIs) broadly have lower toxicity than older agents [<xref ref-type="bibr" rid="b12">12</xref>], but have also been associated with significant adverse effects including cardiovascular effects, sexual dysfunction [<xref ref-type="bibr" rid="b8">8</xref>], weight gain [<xref ref-type="bibr" rid="b13">13</xref>], electrolyte disturbances, haematological effects [<xref ref-type="bibr" rid="b8">8</xref>] and hepatic damage [<xref ref-type="bibr" rid="b14">14</xref>]. A possible increase in suicidal thoughts and self-destructive behaviour in paediatric patients prescribed antidepressants has been documented [<xref ref-type="bibr" rid="b15">15</xref>] and regulatory warnings have been extended for young people up to the age of 25 years [<xref ref-type="bibr" rid="b16">16</xref>]. Most treatment guidelines recommend clinician vigilance for adverse symptoms or caution when administering antidepressants to people from high risk populations, including those with a prior history of medication sensitivity, the medically unwell [<xref ref-type="bibr" rid="b17">17</xref>], the elderly [<xref ref-type="bibr" rid="b18">18</xref>], adolescents [<xref ref-type="bibr" rid="b19">19</xref>] and pregnant or breastfeeding women [<xref ref-type="bibr" rid="b20">20</xref>]. Specific recommendations are, however, not widely available.</p><p>MDD is frequently comorbid with physical problems and illnesses including obesity [<xref ref-type="bibr" rid="b21">21</xref>], cardiovascular disease and diabetes mellitus [<xref ref-type="bibr" rid="b22">22</xref>], substance misuse and other mental disorders, reflecting both antecedent and consequence pathways [<xref ref-type="bibr" rid="b23">23</xref>]. This may affect the efficacy of treatments for MDD as well as increasing the vulnerability of patients to adverse effects and risk of harmful drug interactions.</p><p>Non-pharmacological treatments for MDD including psychotherapy [<xref ref-type="bibr" rid="b24">24</xref>] have also been associated with adverse events. Such adverse effects are, however, less frequently reported. Complementary and alternative treatments can be associated with adverse events [<xref ref-type="bibr" rid="b25">25</xref>] and pharmacological interactions. Even exercise, which has an established evidence base in depression treatment [<xref ref-type="bibr" rid="b26">26</xref>], may be associated with adverse effects in individuals with comorbid cardiovascular disease, prolonged QT interval or who attempt strenuous activity without a period of adjustment [<xref ref-type="bibr" rid="b27">27</xref>]. However, gradual exercise training for rehabilitation following a major cardiac event in depressed individuals is associated with 73% reduced mortality when compared to depressed individuals who did not participate in exercise training [<xref ref-type="bibr" rid="b28">28</xref>].</p><p>Guidelines exist for safety monitoring of treatments for schizophrenia [<xref ref-type="bibr" rid="b29">29</xref>], bipolar disorder [<xref ref-type="bibr" rid="b30">30</xref>] and for specific medications (e.g. clozapine) [<xref ref-type="bibr" rid="b31">31</xref>], but there are none for clinical depression. Previous Australian guidelines focus on treatment algorithms [<xref ref-type="bibr" rid="b32">32</xref>]. Guidelines for baseline screening and safety monitoring of antidepressant treatments may significantly reduce risks of adverse events.</p><sec sec-type="methods"><title>Method</title><p>Data were sourced by a literature search using MEDLINE and a manual search of scientific journals to identify relevant articles. Searches were conducted on multiple occasions by individual co-authors. Draft guidelines were prepared and serially revised in an iterative manner until all co-authors gave final approval of content. The process was completed over an 18 month period in 2010 and 2011.</p><sec><title>The decision to treat</title><p>The management of depression should include an appropriate diagnostic work up, especially to exclude organic or self-limiting determinants. A person's individual risk, prior treatment history and therapeutic preferences should be assessed prior to treatment selection.</p><p>Choice of treatment must carefully balance efficacy, potential harms and patient preference, facilitating an informed choice for patients to treatment that best matches their presentation [<xref ref-type="bibr" rid="b33">33</xref>]. The following sections will address evidence-based pre-treatment screening and monitoring of treatment of depression and are shown in <xref ref-type="table" rid="tbl1">Table 1</xref>. Baseline screening and monitoring recommendations for specific depression augmentation strategies (e.g. lithium [<xref ref-type="bibr" rid="b30">30</xref>], the atypical antipsychotics [<xref ref-type="bibr" rid="b29">29</xref>]) are reviewed extensively elsewhere and hence are not included below. Similarly, monitoring of psychological therapy is beyond the scope of this paper [<xref ref-type="bibr" rid="b24">24</xref>].</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Monitoring recommendations for patients treated for major depressive disorder</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Monitoring parameter</th><th align="center" rowspan="1" colspan="1">Agent</th><th align="center" rowspan="1" colspan="1">Frequency</th><th align="center" rowspan="1" colspan="1">Comments</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Electrocardiogram for QT prolongation</td><td align="left" rowspan="1" colspan="1">Tricylic antidepressants</td><td align="left" rowspan="1" colspan="1">Baseline, after initial dose titration and at dose changes</td><td align="left" rowspan="1" colspan="1">More caution is indicated in children and the elderly and at higher doses</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver function test</td><td align="left" rowspan="1" colspan="1">Agents with hepatic liability</td><td align="left" rowspan="1" colspan="1">At the start of treatment and at 6, 12 and 24 weeks of treatment and when clinically indicated</td><td align="left" rowspan="1" colspan="1">Mandated for agomelatine, other agents as indicated</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI and waist circumference</td><td align="left" rowspan="1" colspan="1">Agents with known weight gain liability</td><td align="left" rowspan="1" colspan="1">Baseline At one month and at 6 month intervals</td><td align="left" rowspan="1" colspan="1">More caution with mirtazapine, mianserin, tricyclics and MAOIs</td></tr><tr><td align="left" rowspan="1" colspan="1">Vitamin D, B12, folate, zinc, magnesium</td><td align="left" rowspan="1" colspan="1">All antidepressants</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">If indicated</td></tr><tr><td align="left" rowspan="1" colspan="1">Electrolytes for hyponatraemia</td><td align="left" rowspan="1" colspan="1">SSRIs, mirtazapine, SNRIs and TCAs</td><td align="left" rowspan="1" colspan="1">At baseline and after one month if clinically indicated in high risk groups, especially the elderly (&#x0003e; 65 years)</td><td align="left" rowspan="1" colspan="1">More frequent monitoring in elderly or those with existing hyponatraemia, follow up testing of urine and serum osmolality</td></tr><tr><td align="left" rowspan="1" colspan="1">Full Blood Examination to detect neutropaenia and thrombocytopaenia</td><td align="left" rowspan="1" colspan="1">Mirtazapine and mianserin</td><td align="left" rowspan="1" colspan="1">If clinically indicated</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Suicidality</td><td align="left" rowspan="1" colspan="1">All antidepressants, especially SSRIs in adolescents</td><td align="left" rowspan="1" colspan="1">Weekly in the first few weeks of treatment. More frequent monitoring may be required in more severely depressed or suicidal patients</td><td align="left" rowspan="1" colspan="1">Particular caution in adolescents Warn next of kin/carer and ask for their collateral monitor as well</td></tr><tr><td align="left" rowspan="1" colspan="1">Antidepressant side-effect monitoring or Checklist</td><td align="left" rowspan="1" colspan="1">All antidepressants</td><td align="left" rowspan="1" colspan="1">At one month and with reviews</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Bone mineral density</td><td align="left" rowspan="1" colspan="1">SSRIs</td><td align="left" rowspan="1" colspan="1">As clinically indicated in high risk groups</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Blood pressure monitoring</td><td align="left" rowspan="1" colspan="1">Venlafaxine, tricyclics and MAOIs</td><td align="left" rowspan="1" colspan="1">With venlafaxine, tricyclics and MAOIs; at baseline, and with significant dose increase and 3-6 monthly after stabilization</td><td align="left" rowspan="1" colspan="1">Closer monitoring of MAOI's in first weeks (tolerance occurs)</td></tr></tbody></table></table-wrap></sec><sec><title>Baseline screening prior to commencement of treatment</title><sec><title>Patient history and physical examination</title><p>Obtaining a thorough patient history and examination prior to commencing treatment is important in order to (i) determine whether medical factors may be influencing the current presentation, (ii) determine and document any risk factors which may increase susceptibility to adverse outcomes, (iii) establish baseline measures of physical and mental health in order to monitor treatment efficacy and safety, and (iv) clarify depressive type and assist treatment selection.</p><p>Specific medical history information that can impact on monitoring and influence outcome includes substance use (e.g. alcohol [<xref ref-type="bibr" rid="b34">34</xref>], tobacco [<xref ref-type="bibr" rid="b35">35</xref>,<xref ref-type="bibr" rid="b36">36</xref>] and prescribed and illicit drugs), physical activity [<xref ref-type="bibr" rid="b37">37</xref>,<xref ref-type="bibr" rid="b38">38</xref>], life events, diet [<xref ref-type="bibr" rid="b39">39</xref>,<xref ref-type="bibr" rid="b40">40</xref>] and chronic and medical illness [<xref ref-type="bibr" rid="b41">41</xref>] as well as family history, history of illness and treatment history [<xref ref-type="bibr" rid="b42">42</xref>]. Personal or family history of thyroid, cardiac and cerebrovascular disease, hypertension, dyslipidaemia and/or diabetes mellitus should alert clinicians to increased risks associated with antidepressant treatments, and guide targeted baseline assessments.</p><p>Although uncommon, organic causes of depressive symptoms should be considered and evaluated before treatment is initiated. Organic causes include metabolic disorders, some vitamin deficiencies (e.g. vitamin D [<xref ref-type="bibr" rid="b43">43</xref>, <xref ref-type="bibr" rid="b44">44</xref>], folate, B12, magnesium [<xref ref-type="bibr" rid="b45">45</xref>], zinc [<xref ref-type="bibr" rid="b46">46</xref>]), chronic pain, sleep apnoea, cancer, cerebrovascular disease, neurological disorders, traumatic brain injury, autoimmune disease (systemic lupus erythematosus), some infections (hepatitis and HIV) and endocrine disorders [<xref ref-type="bibr" rid="b47">47</xref>]. Thyroid disease is an occasional medical cause of depressive symptom onset or persistence whilst Cushing's and Addison's disease are rare causes [<xref ref-type="bibr" rid="b48">48</xref>].</p></sec><sec><title>Blood and serological testing</title><p>Some organic causes of depressive symptoms can be detected through routine blood screening. The following tests may have a role in baseline screening prior to anti-depressant treatment.</p></sec><sec><title>Thyroid stimulating hormone (TSH) and thyroid hormones</title><p>Hyperthyroidism and hypothyroidism can be associated with mood disorders. Symptoms of hyperthyroidism include dysphoria, anxiety, restlessness, emotional lability and impaired concentration. Symptoms of hypothyroidism include psychomotor retardation, decreased appetite, fatigue and lethargy, which when severe mimics melancholic depression [<xref ref-type="bibr" rid="b48">48</xref>]. Subclinical and past thyroid dysfunction is a risk factor for depression and antidepressant non-response [<xref ref-type="bibr" rid="b49">49</xref>]. Identification of abnormal thyroid function in depressed patients should prompt correction of thyroid hormone levels (T3 and T4), and where necessary, referral to an endocrinologist for further investigation. Depressive symptoms may resolve with correction of thyroid hormone levels. However, for some patients depressive symptoms may persist and require additional treatment.</p></sec><sec><title>Full blood examination (FBE)</title><p>Full blood examination (FBE) can identify anaemia, potential underlying infections and blood dyscrasias that may contribute to depressive symptoms. Anaemia can induce fatigue and may be misinterpreted as, or contribute to, depressive symptoms. Alterations in leucocytes may alert to the presence of an underlying infection or other pathological process (e.g. cancer).</p></sec><sec><title>Liver function tests</title><p>Diseases of the liver have been associated with depression [<xref ref-type="bibr" rid="b50">50</xref>], and some antidepressant treatments are associated with hepatotoxicity [<xref ref-type="bibr" rid="b14">14</xref>]. Impaired liver function at baseline should prompt further investigation to determine and treat any hepatic disease. High levels of GGT and AST may suggest comorbid alcohol abuse, especially if concurrent with an increased mean cell volume [<xref ref-type="bibr" rid="b51">51</xref>]. Intravenous drug use may result in hepatitis C and cause abnormal liver function tests (LFT).</p></sec><sec><title>Screening for viral and other infections</title><p>Viral infections including human immunodeficiency virus (HIV) [<xref ref-type="bibr" rid="b52">52</xref>], hepatitis C [<xref ref-type="bibr" rid="b53">53</xref>], West Nile virus [<xref ref-type="bibr" rid="b54">54</xref>] and Epstein-Barr virus [<xref ref-type="bibr" rid="b55">55</xref>, <xref ref-type="bibr" rid="b56">56</xref>] are associated with depression, albeit uncommonly. This may relate directly to the infection or be consequent to elevated levels of cytokines that may themselves be biomarkers of risk for depression [<xref ref-type="bibr" rid="b57">57</xref>]. Fatigue is common following acute infective illness [<xref ref-type="bibr" rid="b58">58</xref>] and may be mistakenly attributed as a depressive symptom. In addition, antiviral treatment, most notably PEGylated interferon, can cause episodes of depression [<xref ref-type="bibr" rid="b59">59</xref>]. Though uncommon in contemporary practice, non-viral infections such as syphilis [<xref ref-type="bibr" rid="b60">60</xref>] can also cause depressive symptoms. Fatigue and depressive symptoms may be a response to activation of the immune system [<xref ref-type="bibr" rid="b61">61</xref>], suggesting that broader associations between infections, treatments for infections and the manifestation of depressive symptoms may exist. Prior to commencing antidepressants, a detailed history of past infectious illness and treatments should be acquired, and supplemented with serological testing and testing of inflammatory markers (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)) if current infection is suspected.</p></sec><sec><title>Alcohol and illicit substance screen</title><p>Alcohol abuse or dependence are causal factors contributing to depression [<xref ref-type="bibr" rid="b62">62</xref>]. Many other substances have also been associated with depression; however, the direction of causality has not been clearly determined. Smoking can increase the risk of depression [<xref ref-type="bibr" rid="b35">35</xref>], through direct neurotransmitter mechanisms and via pharmacokinetic drug interactions (e.g. tar components inducing hepatic isoenzymes CYP1A1, CYP1A2 and possibly CYP2E1) and pharmacodynamic drug interactions with nicotine [<xref ref-type="bibr" rid="b63">63</xref>]. Depressive symptoms may also emerge with smoking cessation [<xref ref-type="bibr" rid="b64">64</xref>]. Cannabis, amphetamine and cocaine use are also associated with depression, and intoxication or withdrawal can be confused with a mood disorder [<xref ref-type="bibr" rid="b65">65</xref>]. Furthermore, comorbid alcohol or substance abuse are associated with antidepressant treatment resistance and non-adherence [<xref ref-type="bibr" rid="b66">66</xref>]. Obtaining a detailed drug and alcohol history is essential in patients with depression, although clinicians should be cognisant of potential underreporting. Blood or urine screening may be useful in selective cases although such screening only identifies substances present at the time of the test. Collateral information from relatives and friends, as well as other health professionals is invaluable to fully explore substance and alcohol issues. Raised transaminases, elevated carbohydrate deficient transferrin and increased mean cell volume are a clue as to the presence of alcohol abuse.</p></sec><sec><title>Screen for prescription medications</title><p>Several medications are known to induce depressive symptoms. Interferon and other immune active agents (previously mentioned) may be directly causative of depressive episodes [<xref ref-type="bibr" rid="b59">59</xref>]. Benzodiazepine use may be associated with depression [<xref ref-type="bibr" rid="b67">67</xref>]. Opiates are frequently utilized agents especially in the context of chronic pain. Depression and chronic pain are commonly comorbid and iterative, and it is possible that chronic opiate use has a noxious effect on mood [<xref ref-type="bibr" rid="b68">68</xref>,<xref ref-type="bibr" rid="b69">69</xref>]. Other potential mood modifying agents include some steroidal and other hormonal treatments [<xref ref-type="bibr" rid="b70">70</xref>,<xref ref-type="bibr" rid="b71">71</xref>], cardiovascular drugs, cholesterol lowering agents, parkinsonian agents, antibiotic agents [<xref ref-type="bibr" rid="b72">72</xref>], antineoplastic agents [<xref ref-type="bibr" rid="b73">73</xref>], anticonvulsants [<xref ref-type="bibr" rid="b74">74</xref>], typical antipsychotics and analgesics [<xref ref-type="bibr" rid="b75">75</xref>-<xref ref-type="bibr" rid="b78">78</xref>]. If there is a temporal association of the onset of depression and the commencement of a medication, then an assumption of causality is practicable.</p></sec><sec><title>Vitamin D</title><p>A high prevalence of vitamin D insufficiency is found in most western societies [<xref ref-type="bibr" rid="b79">79</xref>] particularly amongst the elderly [<xref ref-type="bibr" rid="b80">80</xref>-<xref ref-type="bibr" rid="b83">83</xref>]. Psychiatric cohorts appear to have even higher rates of Vitamin D insufficiency [<xref ref-type="bibr" rid="b43">43</xref>], with 58% of inpatients in one study having vitamin D insufficiency and 11 % showing deficiency. Low levels of vitamin D, which are common in winter, may contribute to seasonal affective disorder (SAD) [<xref ref-type="bibr" rid="b84">84</xref>,<xref ref-type="bibr" rid="b85">85</xref>] and a higher likelihood of developing a depressed mood [<xref ref-type="bibr" rid="b86">86</xref>,<xref ref-type="bibr" rid="b87">87</xref>]. There are some data, albeit inconsistent, that vitamin D supplementation may prevent or improve depressive symptoms [<xref ref-type="bibr" rid="b88">88</xref>,<xref ref-type="bibr" rid="b89">89</xref>]. While a comprehensive picture of the role of vitamin D in depression is yet to emerge, the high yield from screening and the simplicity of supplementation suggests that screening may be worthwhile. There is some evidence that folate, vitamin B12 magnesium and selenium, amongst other nutrients, are deficient in some individuals with depression, and inconsistent data that supplementation may be of value [<xref ref-type="bibr" rid="b45">45</xref>,<xref ref-type="bibr" rid="b90">90</xref>-<xref ref-type="bibr" rid="b92">92</xref>]. The absence of quality data limits evidence-based recommendations regarding screening, but this should be considered if indicated by history.</p></sec><sec><title>Cognitive neuropsychological testing</title><p>Depression often overlaps with dementia and mild cognitive impairment in elderly patients. Late onset depression may be a prodrome of cognitive decline [<xref ref-type="bibr" rid="b93">93</xref>] and depressive symptoms can be confused with dementia [<xref ref-type="bibr" rid="b94">94</xref>]. In patients with late-onset depression, diagnostic work up may require formal assessment of cognitive impairment. Late onset vascular depression has been associated with brain small vessel disease demonstrated by hyperintensities on MRI scans [<xref ref-type="bibr" rid="b95">95</xref>]. Patients with consistent symptoms should be assessed for vascular risk factors such as smoking, hypertension and diabetes.</p></sec><sec><title>Metabolic profile, waist circumference and body mass index</title><p>Many antidepressants are associated with weight gain, but depression, particularly atypical depression, can cause weight gain independent of medication [<xref ref-type="bibr" rid="b21">21</xref>,<xref ref-type="bibr" rid="b96">96</xref>]. Metabolic syndrome is a cluster of risk factors which identify individuals at high risk for cardiovascular disease and type II diabetes mellitus [<xref ref-type="bibr" rid="b97">97</xref>]. The prevalence of metabolic syndrome in patients with current major depression was found to be 56% in a Finnish study [<xref ref-type="bibr" rid="b98">98</xref>] and 25% in a German study [<xref ref-type="bibr" rid="b99">99</xref>]. The relationship between depression and metabolic syndrome is bidirectional, with the syndrome also predictive of increased risk for depression [<xref ref-type="bibr" rid="b100">100</xref>]. A study of depressed inpatients recommended baseline metabolic screening for all hospitalized depressed patients and re-screening during remission [<xref ref-type="bibr" rid="b99">99</xref>].</p><p>Baseline measurements of height, weight (to calculate body mass index) and waist circumference should be undertaken. Patients should be questioned about risk factors for metabolic syndrome including smoking, personal or family history of diabetes, while observational analysis will also commonly suggest those at high risk or likelihood of the syndrome or its complications, such as sleep apnoea. Where appropriate, advice regarding smoking cessation should be given. Guidelines for reviewing risk factors for metabolic syndrome during antidepressant treatment are given in the section detailing ongoing monitoring.</p></sec><sec><title>Cardiovascular disease</title><p>People with depression are at an increased risk of developing cardiovascular disease [<xref ref-type="bibr" rid="b101">101</xref>]. In addition, some antidepressants (in particular TCAs) have associated adverse cardiovascular effects, although most of the newer antidepressants demonstrate low cardiotoxicity. TCAs may affect cardiac conduction and should be used with caution in patients with pre-existing cardiac disorders (especially in those with recent myocardial infarction and arrhythmias) [<xref ref-type="bibr" rid="b102">102</xref>]. Although rare, case reports of adverse cardiac events with newer antidepressants exist, including atrial fibrillation associated with fluoxetine treatment [<xref ref-type="bibr" rid="b102">102</xref>] and mild bradycardia with fluoxetine, fiuvoxamine and paroxetine [<xref ref-type="bibr" rid="b12">12</xref>]. Adverse cardiac events usually occur in patients with additional risk factors such as smoking [<xref ref-type="bibr" rid="b103">103</xref>]. An ECG is probably indicated at baseline and after attainment of therapeutic dosage in individuals with clinical risk factors who have been prescribed agents that can alter the ECG, particularly TCAs. Baseline monitoring of blood pressure and pulse is useful and particularly important if a MAOI or TCA is prescribed [<xref ref-type="bibr" rid="b104">104</xref>]. Venlafaxine can cause tachycardia and increased blood pressure, and this merits monitoring [<xref ref-type="bibr" rid="b105">105</xref>]. Postural hypotension is particularly common with the MAOIs early in the treatment course, although tolerance typically develops. Antidepressant treatment may cause changes in cardiac function that are not outside the clinically normal range [<xref ref-type="bibr" rid="b12">12</xref>], therefore baseline measurements will be required to detect these changes.</p></sec><sec><title>Twenty-four-hour urinary free cortisol</title><p>Hypercortisolaemia and hypocortisolaemia are both associated with depression, although patients typically present with different symptom clusters. Hypocortisolaemia may be more likely to be associated with &#x02018;atypical&#x02019; depression, with symptoms including hypoarousal, hypersomnia, hyperphagia, lethargy, pain, fatigue and relative apathy, whereas hypercortisolaemia may be associated with &#x02018;typical&#x02019; symptoms such as hyper-arousal, anxiety, insomnia and loss of appetite [<xref ref-type="bibr" rid="b106">106</xref>]. It is unclear whether hypothalamic-pituitary-adrenal (HPA) axis activation is causative of depression and consequently information about plasma cortisol is of limited clinical use. The exception is hypercortisolaemia associated with Cushing's syndrome, where depressive symptoms are common and may improve with treatment of the endocrine disorder [<xref ref-type="bibr" rid="b106">106</xref>]. Endocrine and cytokine dysfunction often co-occur [<xref ref-type="bibr" rid="b107">107</xref>], which may also influence mood disturbances. A cushin-goid appearance, impaired glucose tolerance and electrolyte disturbance may point to this diagnosis, and a 24-h urinary free cortisol measurement prior to commencing antidepressant therapy may be useful in this scenario.</p></sec><sec><title>Pregnancy testing</title><p>Screening for pregnancy, including detailed history and consideration of a pregnancy test where indicated is important for women of childbearing age. Pregnancy can influence mood, especially when associated with psycho-social stressors such as an absent partner or when the pregnancy is unplanned [<xref ref-type="bibr" rid="b108">108</xref>]. Pregnancy also raises issues of potential drug-induced teratogenicity; hence knowledge of pregnancy status is important for guiding treatment choices [<xref ref-type="bibr" rid="b20">20</xref>,<xref ref-type="bibr" rid="b109">109</xref>,<xref ref-type="bibr" rid="b110">110</xref>].</p></sec><sec><title>Genetic testing</title><p>Pharmacogenetics (genotype associations to medication response and tolerability) is an emerging area of promise in the safer and more effective prescription of various medications. Some pharmacogenetic tests are commercially available while others are still at an experimental stage. Typically, the tests either probe for polymorphisms of genes involved in neurotransmitter function or probe for polymorphisms of genes involved in drug metabolism [<xref ref-type="bibr" rid="b111">111</xref>]. Currently, the role of genotyping to predict antidepressant adverse effects remains unclear. While there is evidence that genotyping cytochrome P450 polymorphisms detects poor metabolisers and ultra-rapid metabolizers with some level of accuracy, their clinical utility in dose finding remains under investigation [<xref ref-type="bibr" rid="b112">112</xref>,<xref ref-type="bibr" rid="b113">113</xref>]. At present there is no evidence supporting the use of these genetic tests in routine clinical practice, particularly as there is no demonstrated relationship between blood concentrations of the SSRIs or other new antidepressants and clinical efficacy. The role of blood-brain barrier pump polymorphisms is also being explored [<xref ref-type="bibr" rid="b114">114</xref>]. There is limited evidence that certain genotypes are associated with higher rates of emergent suicidality while receiving an antidepressant, but results remain mixed [<xref ref-type="bibr" rid="b115">115</xref>]. At this stage, routine genetic testing of patients commencing antidepressants does not appear to have sufficient evidence to guide recommendations. In selected patients with a history of medication sensitivity or resistance, there may be a limited place for CYP450 genotyping. Should robust evidence of predicting pharmacogenetic response, tolerability and safety associations emerge there may be a greater place for such genotyping in the future.</p></sec><sec><title>Neuroimaging</title><p>Neuroimaging has advanced substantially in the past three decades, with current technology permitting the assessment of neurochemical concentrations within the brain, more detailed appreciation of its structure and connections and an intriguing insight into its functionality. However, a lack of a consensus as regards diagnostic criteria and clinical phenotype of depression has meant that the emergence of characteristic neuroimaging features that have the necessary sensitivity and specificity at an individual level is yet to occur [<xref ref-type="bibr" rid="b116">116</xref>]. The only exception to this may be the use of MRI in cases of late onset depression to confirm the presence of underlying causative small vessel disease. Late onset depression may at times progress to dementia, and MRI will provide a baseline for future assessments.</p></sec><sec><title>Screening for electroconvulsive therapy</title><p>In most jurisdictions, electroconvulsive therapy (ECT) is subject to specific legislative constraints and treatment needs to respect these limitations [<xref ref-type="bibr" rid="b117">117</xref>]. Patients should be assessed, including relevant investigations into their general physical health prior to receiving ECT. Acutely ill patients should only receive ECT as an inpatient, at least until their condition stabilizes, as suicide risk may increase in the early phase of treatment [<xref ref-type="bibr" rid="b118">118</xref>]. Investigations should be tailored to the individual patient depending on their history, physical examination and diagnosis. Screening for ECT overlaps considerably with pre-anaes-thetic screening and general recommendations in this document.</p><p>Uncontrolled hypertension and cerebral tumours are absolute contraindications to ECT. Blood pressure must be assessed. Cochlear implants are a contraindication, unless removed. Cardiac pacemakers are not a contraindication, but it is essential to know the underlying cardiac rhythm and to liaise with the patient's cardiologist on pacemaker management with ECT. Cardiologist opinion should also be sought with patients who have severe aortic stenosis. Anaesthetic monitoring includes ECG, pO<sub>2</sub> and pCO<sub>2</sub>, and respiratory rate monitoring of pO<sub>2</sub> and pCO<sub>2</sub> as well as pulse, blood pressure, respirations, and conscious state are critical in the recovery area.</p></sec><sec><title>Biomarkers</title><p>An emerging research area is that of biomarkers in depression. New data suggest certain biomarkers, including cytokines such as CRP [<xref ref-type="bibr" rid="b128">128</xref>] and leptin [<xref ref-type="bibr" rid="b129">129</xref>], may be indicative of risk of development of de-novo depression. Other biomarkers have demonstrated a cross-sectional association with depression, such as measures of oxidative stress and neurotrophins [<xref ref-type="bibr" rid="b130">130</xref>]. These markers are currently of research interest only, and while provisional evidence suggests potential roles they may shed light on clinical course and outcome [<xref ref-type="bibr" rid="b131">131</xref>], data are too preliminary to merit incorporation in routine clinical screening.</p></sec></sec><sec><title>Ongoing monitoring during antidepressant treatment</title><sec><title>Suicide</title><p>After initiating antidepressant treatment, patients should be monitored for suicide risk. A thorough review of suicide monitoring is beyond the scope of this review, however practice guideline are available elsewhere [<xref ref-type="bibr" rid="b119">119</xref>, <xref ref-type="bibr" rid="b120">120</xref>].</p></sec><sec><title>Obesity and metabolic syndrome</title><p>Waist circumference and body mass index should be monitored, particularly in patients treated with antidepres-sants associated with weight gain [<xref ref-type="bibr" rid="b121">121</xref>]. It is unclear whether being overweight at baseline is associated with further weight increase with antidepressant exposure. Most studies have found no clear association between antidepressant-induced weight gain and baseline measures [<xref ref-type="bibr" rid="b122">122</xref>]. In some cases antidepressant treatment may reduce weight and abdominal fat by decreasing anxiety and regulating dietary patterns [<xref ref-type="bibr" rid="b123">123</xref>]. A naturalistic study found that weight gain in the first week of antidepressant treatment was a significant predictor of sustained weight gain [<xref ref-type="bibr" rid="b13">13</xref>]. There is limited evidence that ethnicity may influence weight increases with antidepressant treatment [<xref ref-type="bibr" rid="b124">124</xref>]. Early detection of weight gain and intervention to prevent sustained weight gain may have significant benefits. Monitoring of the metabolic profile may be prudent at 3, 6 and 12 months, then yearly, in all patients, not just in patients who are obese or overweight. While TCAs, MAOIs, mianserin and mirtazapine are most associated with weight gain [<xref ref-type="bibr" rid="b121">121</xref>], problems may arise with other newer antidepressants. Paroxetine may be more likely to cause weight gain than other SSRIs, and bupropion may be less likely than the SSRIs [<xref ref-type="bibr" rid="b125">125</xref>]. Particular attention should be given to those patients receiving augmentation or combination pharmacotherapy, especially with atypical antipsychotics [<xref ref-type="bibr" rid="b126">126</xref>].</p></sec><sec><title>Cardiovascular status</title><p>Cardiovascular status may need monitoring during antidepressant treatment. Electrocardiography (ECG) is recommended for patients being treated with the older antidepressants, especially in those over 45 years of age and those with cardiovascular disorders [<xref ref-type="bibr" rid="b12">12</xref>]. ECG should be considered prior to initiation of a TCA, and at steady state, for monitoring the QTc interval and for development of arrhythmias [<xref ref-type="bibr" rid="b127">127</xref>]. It may also be considered prior to commencing treatment with an SNRI in high-risk individuals. QT prolongation is a common finding in the elderly. It can lead to Torsades de Pointes (a re-entrant tachycardia), resulting in ventricular fibrillation and sudden cardiac death. It is possible that such outcomes are under-reported. TCAs are known to cause QT prolongation by autonomic effects and effect on rapid outward potassium currents, resulting in delayed repolarization. Patients who have already been treated with a class I antiarrhythmic agent (Na<sup>+</sup>channel blocking) [<xref ref-type="bibr" rid="b12">12</xref>] and those who metabolize tricyclics more slowly (cytochrome CYP2D6 poor metabolizer phenotype) may be at increased risk [<xref ref-type="bibr" rid="b128">128</xref>]. Electrolyte disturbances, which can be a consequence of some antidepressants, increase the risk of arrhythmias [<xref ref-type="bibr" rid="b129">129</xref>].</p><p>SSRIs have also been rarely associated with cases of Torsades de Pointes. There were 20 such cases associated with fluoxetine, with one fatality, reported by WHO adverse drug effect monitoring between 1983 and 1999 [<xref ref-type="bibr" rid="b130">130</xref>]. Cases associated with SSRIs, however, remain infrequent, sporadic and often involve overdose or drug interactions. Overdose of tricyclics and SSRIs mimic the appearance of Brugada's syndrome with right bundle branch block and ST elevation [<xref ref-type="bibr" rid="b131">131</xref>], suggesting some drugs (including fiuoxetine and amitriptyline) may also block cardiac sodium channels. Baseline ECG is important in excluding familial long QT syndrome and to reveal T or U wave abnormalities. Repeat ECG monitoring of QT prolongation may be indicated when significant dose changes are made withTCAs. ECG monitoring with SSRI treatment may be useful in high risk cases, though this is usually unnecessary.</p></sec><sec><title>Blood dyscrasias</title><p>There are rare reports of blood dyscrasias with antide-pressant administration. Case reports have included mian-serin- or mirtazapine-induced neutropenia [<xref ref-type="bibr" rid="b132">132</xref>] and citalopram-induced thrombocytopenia [<xref ref-type="bibr" rid="b133">133</xref>]. Agranulo-cytosis induced by newer antidepressants is much less common than that which was reported with tricyclic or tetracyclic antidepressants [<xref ref-type="bibr" rid="b8">8</xref>]. Monitoring of the full blood examination in patients treated with antidepressants may be prudent when rechallenging patients with a history of a blood dyscrasia. With mirtazapine and mian-serin, one should be alert for emergent symptoms such as fever, sore throat, stomatitis or other signs of infections. If such symptoms occur, haematological investigations should be undertaken and the treatment stopped. Given the very low yield of screening for this very rare adverse event, routine haematological monitoring is not justified.</p></sec><sec><title>Hepatotoxicity</title><p>Numerous antidepressants have been found to affect the liver. The MAOIs and the TCAs are associated with an appreciable though infrequent risk of hepatotoxicity [<xref ref-type="bibr" rid="b134">134</xref>]. However, changes in hepatic enzyme levels have rarely been reported for SSRIs and other newer antidepressants including paroxetine [<xref ref-type="bibr" rid="b135">135</xref>-<xref ref-type="bibr" rid="b137">137</xref>], sertraline [<xref ref-type="bibr" rid="b138">138</xref>,<xref ref-type="bibr" rid="b139">139</xref>], fiuoxetine [<xref ref-type="bibr" rid="b140">140</xref>,<xref ref-type="bibr" rid="b141">141</xref>], mianserin [<xref ref-type="bibr" rid="b142">142</xref>], mirtazapine [<xref ref-type="bibr" rid="b143">143</xref>,<xref ref-type="bibr" rid="b144">144</xref>], bupropi on [<xref ref-type="bibr" rid="b145">145</xref>],trazodone [<xref ref-type="bibr" rid="b146">146</xref>,<xref ref-type="bibr" rid="b147">147</xref>], nefazodone [<xref ref-type="bibr" rid="b14">14</xref>], venlafaxine [<xref ref-type="bibr" rid="b146">146</xref>], duloxetine [<xref ref-type="bibr" rid="b148">148</xref>] and agomelatine [<xref ref-type="bibr" rid="b149">149</xref>]. Disentangling these rare reports from baseline-associated factors is difficult. Antidepressant-induced hepatotoxicity is usually an idiosyncratic adverse drug reaction of low prevalence characterized by elevated ALT and sometimes by jaundice. The consequences of antidepressant-induced changes in hepatic function can range from asymptomatic changes [<xref ref-type="bibr" rid="b144">144</xref>] to fatal outcomes [<xref ref-type="bibr" rid="b145">145</xref>]. It is unclear whether the use of antidepressants may aggravate existing hepatic disease. Pre-existing hepatic disease may alter the metabolic clearance of some antidepressants and may necessitate dose adjustment [<xref ref-type="bibr" rid="b134">134</xref>].</p><p>It does not appear that susceptibility to antidepressant-induced hepatotoxicity can be predicted by LFT or ALT before commencing antidepressant treatment. Therefore these tests are not used as a baseline screen to monitor risk for developing <italic>de-novo</italic> hepatic injury in response to antidepressant exposure [<xref ref-type="bibr" rid="b134">134</xref>]. However, they may be useful for detecting pre-existing hepatic injury and for establishing a baseline for patients before commencing antidepressant treatment and are required before commencing treatment with agomelatine. Antidepressant-induced hepatotoxicity typically occurs within the first few months of treatment.</p><p>Nefazodone has been withdrawn from the Australian market as a result of cases of fatal hepatotoxicity [<xref ref-type="bibr" rid="b150">150</xref>,<xref ref-type="bibr" rid="b151">151</xref>]. Elevations of serum transaminases are documented in clinical trials of agomelatine but these changes usually return to normal levels after discontinuation. The European Medicines Agency has recommended a liver function test for patients treated with agomelatine at the start of treatment and at 6, 12 and 24 weeks of treatment and when clinically indicated [<xref ref-type="bibr" rid="b152">152</xref>].</p><p>Lucena <italic>et al</italic>. [<xref ref-type="bibr" rid="b134">134</xref>] state that hepatotoxicity is an uncommon and unpredictable idiosyncratic reaction, and that there is no evidence that routine monitoring reduces the rate of hepatotoxicity with antidepressants in general.</p><p>After a hepatotoxic reaction, if an antidepressant rechallenge is indicated, monthly liver functions test for the first 6 months of treatment, with discontinuation of treatment if ALT values exceed (by three times) the upper limit of the normal range, if bilirubin levels rise, or if signs or symptoms of liver dysfunction are present, are recommended by the authors. If an individual develops increased serum transaminases, tests should be repeated within 48 h. After discontinuation, monitoring can be continued to ensure that liver function returns to the normal range. Rechallenge should be considered with caution, and only after careful consideration of risks and benefits. Adverse reactions to an antidepressant rechallenge are not uncommon [<xref ref-type="bibr" rid="b150">150</xref>] and sometimes a more severe antidepressant-induced hepatotoxic reaction may occur following antidepressant rechallenge [<xref ref-type="bibr" rid="b139">139</xref>,<xref ref-type="bibr" rid="b153">153</xref>].</p></sec><sec><title>Hyponatraemia</title><p>SSRIs and some other antidepressants have been reported to cause hyponatraemia. The incidence rate in the elderly is 4.7 cases/1000 people treated/year [<xref ref-type="bibr" rid="b154">154</xref>,<xref ref-type="bibr" rid="b155">155</xref>], but is much lower in younger age groups. It should be suspected if an elderly patient becomes confused or develops a frank delirium after commencement of an antidepressant. It may be why a person's mood may inexplicably worsen. Deaths associated with hyponatraemia have been reported [<xref ref-type="bibr" rid="b156">156</xref>]. Liu <italic>et al</italic>. [<xref ref-type="bibr" rid="b157">157</xref>] reported on 736 cases between 1980 and 1995 associated with fiuoxetine, fluvoxamine, paroxetine and sertraline use. Hyponatraemia has also been reported for citalo-pram [<xref ref-type="bibr" rid="b158">158</xref>], escitalopram [<xref ref-type="bibr" rid="b159">159</xref>], duloxetine [<xref ref-type="bibr" rid="b160">160</xref>], mir-tazapine [<xref ref-type="bibr" rid="b161">161</xref>] and reboxetine [<xref ref-type="bibr" rid="b162">162</xref>]. It has been suggested that the risk may be greatest for patients who take fiuoxetine compared to other antidepressants [<xref ref-type="bibr" rid="b154">154</xref>]. SSRIs can induce isovolemic hyponatraemia through a syndrome of inappropriate anti-diuretic hormone (SIADH) secretion [<xref ref-type="bibr" rid="b159">159</xref>]. Hyponatraemia can resolve with antidepressant discontinuation and reoccur with rechallenge [<xref ref-type="bibr" rid="b160">160</xref>]. Baseline screening of patients should include an assessment of risk factors for antidepressant-induced hyponatraemia including advanced age (&#x02265;65 years) [<xref ref-type="bibr" rid="b157">157</xref>], previous history of antidepressant-induced hyponatraemia [<xref ref-type="bibr" rid="b160">160</xref>], low body weight [<xref ref-type="bibr" rid="b155">155</xref>], thiazide use [<xref ref-type="bibr" rid="b163">163</xref>], and the use of other agents that may cause hyponatraemia such as carbamazepine [<xref ref-type="bibr" rid="b164">164</xref>]. Anecdotally, female gender [<xref ref-type="bibr" rid="b163">163</xref>] may also be a risk factor. Most cases of hyponatraemia occur within the first 10 weeks of initiating antidepressant treatment, with 79% occurring in the first 3 weeks [<xref ref-type="bibr" rid="b154">154</xref>]. Regular monitoring of serum sodium in elderly patients has been recommended by some clinicians [<xref ref-type="bibr" rid="b154">154</xref>]. SIADH may also cause a worsening of depressive symptoms [<xref ref-type="bibr" rid="b154">154</xref>,<xref ref-type="bibr" rid="b159">159</xref>] and therefore should be sought and excluded. SIADH should be investigated if a person reports clinical deterioration, cognitive change or dizziness and fatigue after initiation of antidepressant treatment [<xref ref-type="bibr" rid="b159">159</xref>]. There is no current protocol for monitoring serum sodium in patients being treated with antidepressants; however, monitoring after 3-4 weeks of treatment should occur in individuals who match the high risk profile [<xref ref-type="bibr" rid="b155">155</xref>].</p></sec><sec><title>Bone mineral density</title><p>There are recent data indicating that SSRIs may reduce bone mineral density [<xref ref-type="bibr" rid="b165">165</xref>]. Serotonin has a key signalling role in bone cells and influences bone metabolism. Williams <italic>et al</italic>. showed a loss of 6.2% of bone mineral density (BMD) with SSRI treatment [<xref ref-type="bibr" rid="b166">166</xref>]. This magnitude of bone loss has the potential to lead to a 20% increased fracture risk. Bolton <italic>et al</italic>. described SSRI use in older adults being associated with an increased odds of osteoporotic fractures (OR = 1.45), as for other mono-amine antidepressants (OR =1.15), although the relationship was weaker [<xref ref-type="bibr" rid="b167">167</xref>]. These data are supported by a study showing that the risk of non-vertebral fracture for those over 55 years was two-fold for current users of SSRIs compared with non-users of antidepressants [<xref ref-type="bibr" rid="b168">168</xref>]. Preliminary data suggest intra-class differences [<xref ref-type="bibr" rid="b169">169</xref>], with citalopram seeming to have the lowest impact on osteoblast and osteoclast function. There are data indicating that, independent of treatment, people with depression have lower bone mineral density and a higher fracture risk, which is likely to be a compound result of lifestyle factors, disease state and iatrogenic treatment effects. These disease-related effects, combined with the effects on treatment, suggest that screening for bone mineral density should be considered in people on long-term SSRIs, and particularly in high risk groups such as the elderly, women and those with other risk factors such as fracture history, history of falls, low vitamin D, hypogonadism, hyperparathyroidism, thyroid dysfunction, systemic inflammatory disorders, and corticosteroid use. Physical inactivity, alcohol use and smoking are shared lifestyle risk factors for both depression and low BMD.</p></sec><sec><title>Other adverse effects</title><p>Antidepressant treatment is commonly associated with milder adverse effects. The Antidepressant Side-Effect Checklist itemizes 21 adverse events; nausea or vomiting, sexual dysfunction, increased appetite, decreased appetite, sweating, increased body temperature, weight gain, dry mouth, drowsiness, insomnia, blurred vision, headache, constipation, diarrhoea, problems with urination, palpitations, orthostatic dizziness, vertigo, tremor, disorientation, and yawning [<xref ref-type="bibr" rid="b9">9</xref>]. Such adverse effects are important causes of non-adherence to antidepressant treatment [<xref ref-type="bibr" rid="b9">9</xref>] and should therefore be routinely monitored.</p></sec><sec><title>Drug-drug interactions</title><p>Monitoring should take into account that antidepressants may interact with other medications and reduce the therapeutic effect or increase side-effects. Perhaps one of the most important differences between the newer antidepressants is their varying potential to cause drug-drug interactions through inhibition of cytochrome-P450 (CYP) enzymes [<xref ref-type="bibr" rid="b170">170</xref>]. Fluvoxamine, a potent inhibitor of CYP1A2 and CYP2C19, is a particular cause for concern with clinically relevant interactions reported with caffeine, clozapine, benzodiazepines, warfarin and other medications [<xref ref-type="bibr" rid="b170">170</xref>,<xref ref-type="bibr" rid="b171">171</xref>]. SSRIs such fluoxetine and paroxetine, which are potent inhibitors of CYP2D6, can also produce relevant interactions with other medications including beta-blockers, tricyclic antidepressants and antipsychotics such as perphenazine [<xref ref-type="bibr" rid="b172">172</xref>]. Special attention should be given to fluoxetine because inhibitory effects can persist for up to five weeks after discontinuation. Sertraline, citalopram and escitalopram seem to have less interaction potential than the other SSRIs [<xref ref-type="bibr" rid="b170">170</xref>,<xref ref-type="bibr" rid="b173">173</xref>]. Duloxetine andbupropion are moderate inhibitors of CYP2D6, while venlafaxine, mirtazapine and reboxetine are weak inhibitors and are less likely to interact with co-administered medications [<xref ref-type="bibr" rid="b173">173</xref>]. These factors should be taken into account when starting an antidepressant and in some cases may require dose adjustment.</p></sec></sec></sec><sec sec-type=""><title>Discussion</title><p>Choosing a treatment that offers the optimal risk-benefit ratio for a given individual is typically complex. The balance between the patient's prior history of treatment response and tolerability, their current clinical profile and needs, their medical status and personal risks, and the differential tolerability profiles of the drug choices and their efficacy data need to be struck. Optimal safety monitoring is part of a system of care committed to a culture of patient safety. The treating clinician is primarily responsible for decisions regarding treatment choice, making these decisions on the basis of shared decision making, in the context of a collaborative alliance, and communicating the risks and benefits to the patient. In divergent settings, the monitoring arrangements need to vary. Computerized electronic medical records or checklists with reminder prompts may help with safety monitoring; however, systems for lines of communication, co-ordination of monitoring practices and for the interpretation of results need to be developed. If adverse events emerge, the re-balanced risk-benefit ratio needs to be evaluated on an individual basis. Decisions regarding further investigations, referrals to specialist care or the need for treatment changes will need to be made.</p><p>Safety monitoring guidelines are developed from indirect data, which are frequently limited and drawn from clinical trial data and surveillance monitoring. Almost no direct studies are available on the utility, cost-benefit ratios, yield or practical implementation of safety monitoring guidelines. The guidelines themselves are the product of an imperfect process of literature review moulded by consensus opinion. They therefore need to be used flexibly and should be moulded by clinical acumen. The recommendations should be adapted to the needs of individual patients, taking into account broad risk factors such as age, general health, comorbidity, polypharmacy, capacity for adherence to monitoring procedures, and clinical diagnosis. It needs to be stressed that these guidelines do not represent a fixed standard of care in a medico-legal context. The principal goal of these guidelines is to increase the probability of prompt detection and intervention for relatively insidious but clinically significant adverse events. They are likely to evolve with further research on risk, tolerability and safety of treatments.</p></sec></body><back><sec><title>Declaration of interest</title><p>This paper was completed under the auspices of the Australasian Society for Bipolar and Depressive Disorders. It was supported by an unrestricted grant from Servier Laboratories (Australia) Pty. Ltd. 8 Cato Street, Hawthorn VIC 3122, Australia to M.B and S.D. However, at no point in the process of planning, synthesis and writing was there any input or involvement from Servier. The authors alone are responsible for the content and writing of the paper.</p></sec><ref-list><title>References</title><ref id="b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>CF</given-names></name><name><surname>Fontaine</surname><given-names>KR</given-names></name><name><surname>Bruce</surname><given-names>ML</given-names></name><name><surname>Alexopoulos</surname><given-names>GS</given-names></name></person-group><article-title>Population projection of US adults with lifetime experience of depressive disorder by age and sex from year 2005 to 2050</article-title><source>Int J Geriatr Psychiatry</source><year>2008</year><volume>23</volume><fpage>1266</fpage><lpage>1270</lpage><pub-id pub-id-type="pmid">18500691</pub-id></element-citation></ref><ref id="b2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>RC</given-names></name><name><surname>Berglund</surname><given-names>P</given-names></name><name><surname>Demler</surname><given-names>O</given-names></name><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Koretz</surname><given-names>D</given-names></name><name><surname>Merikangas</surname><given-names>KR</given-names></name><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Walters</surname><given-names>EE</given-names></name><name><surname>Wang</surname><given-names>PS</given-names></name></person-group><article-title>The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)</article-title><source>JAMA</source><year>2003</year><volume>289</volume><fpage>3095</fpage><lpage>3105</lpage><pub-id pub-id-type="pmid">12813115</pub-id></element-citation></ref><ref id="b3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittchen</surname><given-names>HU</given-names></name><name><surname>Jacobi</surname><given-names>F</given-names></name></person-group><article-title>Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies</article-title><source>Eur Neuropsychopharmacol</source><year>2005</year><volume>15</volume><fpage>357</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">15961293</pub-id></element-citation></ref><ref id="b4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slade</surname><given-names>T</given-names></name><name><surname>Johnston</surname><given-names>A</given-names></name><name><surname>Oakley</surname><given-names>Browne MA</given-names></name><name><surname>Andrews</surname><given-names>G</given-names></name><name><surname>Whiteford</surname><given-names>H</given-names></name></person-group><article-title>2007 National Survey of Mental Health and Wellbeing: methods and key findings</article-title><source>Aust N Z J Psychiatry</source><year>2009</year><volume>43</volume><fpage>594</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">19530016</pub-id></element-citation></ref><ref id="b5"><label>5</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Worthy</surname><given-names>KC</given-names></name><name><surname>Governale</surname><given-names>LA</given-names></name></person-group><article-title>Trends in outpatient prescription usage in the U.S., 2002 - 2005</article-title><conf-name>Poster presented at the 12th Annual FDA Science Forum</conf-name><conf-date>April 18-20, 2006</conf-date><conf-loc>Washington, DC</conf-loc><comment>board no. 1-13</comment></element-citation></ref><ref id="b6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollingworth</surname><given-names>SA</given-names></name><name><surname>Burgess</surname><given-names>PM</given-names></name><name><surname>Whiteford</surname><given-names>HA</given-names></name></person-group><article-title>Affective and anxiety disorders: prevalence, treatment and antidepressant medication use</article-title><source>Aust N Z J Psychiatry</source><year>2010</year><volume>44</volume><fpage>513</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">20482411</pub-id></element-citation></ref><ref id="b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wille</surname><given-names>SM</given-names></name><name><surname>Cooreman</surname><given-names>SG</given-names></name><name><surname>Neels</surname><given-names>HM</given-names></name><name><surname>Lambert</surname><given-names>WE</given-names></name></person-group><article-title>Relevant issues in the monitoring and the toxicology of antidepressants</article-title><source>Crit Rev Clin Lab Sci</source><year>2008</year><volume>45</volume><fpage>25</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">18293180</pub-id></element-citation></ref><ref id="b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mago</surname><given-names>R</given-names></name><name><surname>Mahajan</surname><given-names>R</given-names></name><name><surname>Thase</surname><given-names>ME</given-names></name></person-group><article-title>Medically serious adverse effects of newer antidepressants</article-title><source>Curr Psychiatry Rep</source><year>2008</year><volume>10</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">18652794</pub-id></element-citation></ref><ref id="b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uher</surname><given-names>R</given-names></name><name><surname>Farmer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Adverse reactions to anti depressants</article-title><source>Br J Psychiatry</source><year>2009</year><volume>195</volume><fpage>202</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">19721108</pub-id></element-citation></ref><ref id="b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>SM</given-names></name><name><surname>Felker</surname><given-names>A</given-names></name></person-group><article-title>Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants</article-title><source>CNS Spectr</source><year>2008</year><volume>13</volume><fpage>855</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">18955941</pub-id></element-citation></ref><ref id="b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>G</given-names></name><name><surname>Fink</surname><given-names>M</given-names></name><etal/></person-group><article-title>Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder</article-title><source>Am J Psychiatry</source><year>2010</year><volume>167</volume><fpage>745</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">20595426</pub-id></element-citation></ref><ref id="b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacher</surname><given-names>P</given-names></name><name><surname>Kecskemeti</surname><given-names>V</given-names></name></person-group><article-title>Cardiovascular side effects of new anti depressants and antipsychotics: new drugs, old concerns?</article-title><source>Curr Pharm Des</source><year>2004</year><volume>10</volume><fpage>2463</fpage><lpage>2475</lpage><pub-id pub-id-type="pmid">15320756</pub-id></element-citation></ref><ref id="b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Himmerich</surname><given-names>H</given-names></name><name><surname>Schuld</surname><given-names>A</given-names></name><name><surname>Haack</surname><given-names>M</given-names></name><name><surname>Kaufmann</surname><given-names>C</given-names></name><name><surname>Pollmacher</surname><given-names>T</given-names></name></person-group><article-title>Early prediction of changes in weight during six weeks of treatment with antidepressants</article-title><source>J Psychiatr Res</source><year>2004</year><volume>38</volume><fpage>485</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">15380398</pub-id></element-citation></ref><ref id="b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvajal</surname><given-names>Garcia-Pando A</given-names></name><name><surname>Garcia del Pozo</surname><given-names>J</given-names></name><name><surname>Sanchez</surname><given-names>AS</given-names></name><name><surname>Velasco</surname><given-names>MA</given-names></name><name><surname>Rueda de Castro</surname><given-names>AM</given-names></name><name><surname>Lucena</surname><given-names>MI</given-names></name></person-group><article-title>Hepatotoxicity associated with the new antidepressants</article-title><source>J Clin Psychiatry</source><year>2002</year><volume>63</volume><fpage>135</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">11874214</pub-id></element-citation></ref><ref id="b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culpepper</surname><given-names>L</given-names></name><name><surname>Davidson</surname><given-names>JR</given-names></name><name><surname>Dietrich</surname><given-names>AJ</given-names></name><name><surname>Goodman</surname><given-names>WK</given-names></name><name><surname>Kroenke</surname><given-names>K</given-names></name><name><surname>Schwenk</surname><given-names>TL</given-names></name></person-group><article-title>Suicidality as a possible side effect of antidepressant treatment</article-title><source>J Clin Psychiatry</source><year>2004</year><volume>65</volume><fpage>742</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">15291649</pub-id></element-citation></ref><ref id="b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leon</surname><given-names>AC</given-names></name></person-group><article-title>The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses</article-title><source>Am J Psychiatry</source><year>2007</year><volume>164</volume><fpage>1786</fpage><lpage>1789</lpage><pub-id pub-id-type="pmid">18056231</pub-id></element-citation></ref><ref id="b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco-Bronson</surname><given-names>K</given-names></name></person-group><article-title>The management of treatment-resistant depression in the medically ill</article-title><source>Psychiatr Clin North Am</source><year>1996</year><volume>19</volume><fpage>329</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">8827193</pub-id></element-citation></ref><ref id="b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>BR</given-names></name><name><surname>Fenn</surname><given-names>H</given-names></name><name><surname>Pompei</surname><given-names>P</given-names></name><name><surname>DeBattista</surname><given-names>C</given-names></name><name><surname>Lembke</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Flores</surname><given-names>B</given-names></name></person-group><article-title>Safety of antidepressants in the elderly</article-title><source>Expert Opin Drug Saf</source><year>2003</year><volume>2</volume><fpage>367</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">12904093</pub-id></element-citation></ref><ref id="b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Dodd</surname><given-names>S</given-names></name></person-group><article-title>Antidepressants and adolescents: the bipolar confound?</article-title><source>Hum Psychopharmacol</source><year>2005</year><volume>20</volume><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">15614839</pub-id></element-citation></ref><ref id="b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisner</surname><given-names>KL</given-names></name><name><surname>Sit</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Major depression and anti-depressant treatment: impact on pregnancy and neonatal outcomes</article-title><source>Am J Psychiatry</source><year>2009</year><volume>166</volume><fpage>557</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">19289451</pub-id></element-citation></ref><ref id="b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>LJ</given-names></name><name><surname>Pasco</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Lifetime psychiatric disorders and body composition: a population-based study</article-title><source>J Affect Disord</source><year>2009</year><volume>118</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">19249106</pub-id></element-citation></ref><ref id="b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turvey</surname><given-names>CL</given-names></name><name><surname>Schultz</surname><given-names>SK</given-names></name><name><surname>Beglinger</surname><given-names>L</given-names></name><name><surname>Klein</surname><given-names>DM</given-names></name></person-group><article-title>A longitudinal community-based study of chronic illness, cognitive and physical function, and depression</article-title><source>Am J Geriatr Psychiatry</source><year>2009</year><volume>17</volume><fpage>632</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">19634203</pub-id></element-citation></ref><ref id="b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>Leonard</surname><given-names>B</given-names></name><etal/></person-group><article-title>(Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: From antioxidants to kinase inhibitors</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2011</year><volume>35</volume><fpage>659</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">21376099</pub-id></element-citation></ref><ref id="b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>G</given-names></name></person-group><article-title>The elephant on the couch: side-effects of psychotherapy</article-title><source>Aust N Z J Psychiatry</source><year>2009</year><volume>43</volume><fpage>787</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">19670051</pub-id></element-citation></ref><ref id="b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breidenbach</surname><given-names>T</given-names></name><name><surname>Hoffmann</surname><given-names>MW</given-names></name><name><surname>Becker</surname><given-names>T</given-names></name><name><surname>Schlitt</surname><given-names>H</given-names></name><name><surname>Klempnauer</surname><given-names>J</given-names></name></person-group><article-title>Drug interaction of St John's wort with cyclosporin</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1912</fpage><pub-id pub-id-type="pmid">10866469</pub-id></element-citation></ref><ref id="b26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname><given-names>GE</given-names></name><name><surname>Morley</surname><given-names>W</given-names></name><name><surname>Campbell</surname><given-names>P</given-names></name><name><surname>Greig</surname><given-names>CA</given-names></name><name><surname>McMurdo</surname><given-names>M</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name></person-group><article-title>Exercise for depression</article-title><source>Cochrane Database Syst Rev</source><year>2009</year><comment>CD004366</comment></element-citation></ref><ref id="b27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>CM</given-names></name><name><surname>Mittleman</surname><given-names>MA</given-names></name><name><surname>Chae</surname><given-names>CU</given-names></name><name><surname>Lee</surname><given-names>IM</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name></person-group><article-title>Triggering of sudden death from cardiac causes by vigorous exertion</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>1355</fpage><lpage>1361</lpage><pub-id pub-id-type="pmid">11070099</pub-id></element-citation></ref><ref id="b28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milani</surname><given-names>RY</given-names></name><name><surname>Lavie</surname><given-names>CJ</given-names></name></person-group><article-title>Impact of cardiac rehabilitation on depression and its associated mortality</article-title><source>Am J Med</source><year>2007</year><volume>120</volume><fpage>799</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">17765050</pub-id></element-citation></ref><ref id="b29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marder</surname><given-names>SR</given-names></name><name><surname>Essock</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Physical health monitoring of patients with schizophrenia</article-title><source>Am J Psychiatry</source><year>2004</year><volume>161</volume><fpage>1334</fpage><lpage>1349</lpage><pub-id pub-id-type="pmid">15285957</pub-id></element-citation></ref><ref id="b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>F</given-names></name><name><surname>Mammen</surname><given-names>OK</given-names></name><etal/></person-group><article-title>The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments</article-title><source>Bipolar Disord</source><year>2009</year><volume>11</volume><fpage>559</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">19689501</pub-id></element-citation></ref><ref id="b31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Fitzsimons</surname><given-names>J</given-names></name><etal/></person-group><article-title>Monitoring the safe use of clozapine: a consensus view from Victoria, Australia</article-title><source>CNS Drugs</source><year>2007</year><volume>21</volume><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">17284094</pub-id></element-citation></ref><ref id="b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>P</given-names></name></person-group><article-title>Australian and New Zealand clinical practice guidelines for the treatment of depression</article-title><source>Aust N Z J Psychiatry</source><year>2004</year><volume>38</volume><fpage>389</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">15209830</pub-id></element-citation></ref><ref id="b33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhi</surname><given-names>GS</given-names></name><name><surname>Adams</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical practice recommendations for depression</article-title><source>Ada Psychiatr Scand Suppl</source><year>2009</year><fpage>8</fpage><lpage>26</lpage></element-citation></ref><ref id="b34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coulson</surname><given-names>CE</given-names></name><name><surname>Williams</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Patterns of alcohol use and associated physical and lifestyle characteristics according to new Australian guidelines</article-title><source>Aust N Z J Psychiatry</source><year>2010</year><volume>44</volume><fpage>946</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">20932209</pub-id></element-citation></ref><ref id="b35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasco</surname><given-names>JA</given-names></name><name><surname>Williams</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Tobacco smoking as a risk factor for major depressive disorder: population-based study</article-title><source>Br J Psychiatry</source><year>2008</year><volume>193</volume><fpage>322</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">18827296</pub-id></element-citation></ref><ref id="b36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Ng</surname><given-names>F</given-names></name><etal/></person-group><article-title>Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania</article-title><source>J Affect Disord</source><year>2008</year><volume>110</volume><fpage>126</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">18280579</pub-id></element-citation></ref><ref id="b37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacka</surname><given-names>FN</given-names></name><name><surname>Pasco</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Lower levels of physical activity in childhood associated with adult depression</article-title><source>J Sci Med Sport</source><year>2011</year><volume>14</volume><fpage>222</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">21147028</pub-id></element-citation></ref><ref id="b38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasco</surname><given-names>JA</given-names></name><name><surname>Williams</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Habitual physical activity and the risk for depressive and anxiety disorders among older men and women</article-title><source>Int Psychogeriatr</source><year>2010</year><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="b39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacka</surname><given-names>FN</given-names></name><name><surname>Kremer</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Associations between diet quality and depressed mood in adolescents: results from the Australian Healthy Neighbourhoods Study</article-title><source>Aust N Z J Psychiatry</source><year>2010</year><volume>44</volume><fpage>435</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">20397785</pub-id></element-citation></ref><ref id="b40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacka</surname><given-names>FN</given-names></name><name><surname>Pasco</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Association of western and traditional diets with depression and anxiety in women</article-title><source>Am J Psychiatry</source><year>2010</year><volume>167</volume><fpage>305</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">20048020</pub-id></element-citation></ref><ref id="b41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batterham</surname><given-names>PJ</given-names></name><name><surname>Christensen</surname><given-names>H</given-names></name><name><surname>Mackinnon</surname><given-names>AJ</given-names></name></person-group><article-title>Modifiable risk factors predicting major depressive disorder at four year follow-up: a decision tree approach</article-title><source>BMC Psychiatry</source><year>2009</year><volume>9</volume><fpage>75</fpage><pub-id pub-id-type="pmid">19930610</pub-id></element-citation></ref><ref id="b42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuithoff</surname><given-names>NP</given-names></name><name><surname>Vergouwe</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A clinical prediction rule for detecting major depressive disorder in primary care: the PRE-DICT-NL study</article-title><source>Fam Pract</source><year>2009</year><volume>26</volume><fpage>241</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">19546117</pub-id></element-citation></ref><ref id="b43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Jacka</surname><given-names>FN</given-names></name><name><surname>Williams</surname><given-names>LJ</given-names></name><name><surname>Ng</surname><given-names>F</given-names></name><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Pasco</surname><given-names>JA</given-names></name></person-group><article-title>Is this D vitamin to worry about? Vitamin D insufficiency in an inpatient sample</article-title><source>Aust N Z J Psychiatry</source><year>2008</year><volume>42</volume><fpage>874</fpage><lpage>878</lpage><pub-id pub-id-type="pmid">18777231</pub-id></element-citation></ref><ref id="b44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Sanders</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Vitamin D deficiency may play a role in depression</article-title><source>Med Hypotheses</source><year>2007</year><volume>69</volume><fpage>1316</fpage><lpage>1319</lpage><pub-id pub-id-type="pmid">17499448</pub-id></element-citation></ref><ref id="b45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacka</surname><given-names>FN</given-names></name><name><surname>Overland</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>R</given-names></name><name><surname>Tell</surname><given-names>GS</given-names></name><name><surname>Bjelland</surname><given-names>I</given-names></name><name><surname>Mykletun</surname><given-names>A</given-names></name></person-group><article-title>Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study</article-title><source>Aust N Z J Psychiatry</source><year>2009</year><volume>43</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">19085527</pub-id></element-citation></ref><ref id="b46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szewczyk</surname><given-names>B</given-names></name><name><surname>Poleszak</surname><given-names>E</given-names></name><etal/></person-group><article-title>Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action</article-title><source>Pharmacol Rep</source><year>2008</year><volume>60</volume><fpage>588</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">19066406</pub-id></element-citation></ref><ref id="b47"><label>47</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>MM</given-names></name><name><surname>Katona</surname><given-names>CLE</given-names></name></person-group><source>Depression and physical illness</source><year>1997</year><publisher-loc>Chichester</publisher-loc><publisher-name>Wiley</publisher-name></element-citation></ref><ref id="b48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Goetz</surname><given-names>T</given-names></name><name><surname>Glenn</surname><given-names>T</given-names></name><name><surname>Whybrow</surname><given-names>PC</given-names></name></person-group><article-title>The thyroid-brain interaction in thyroid disorders and mood disorders</article-title><source>J Neuroendocrinol</source><year>2008</year><volume>20</volume><fpage>1101</fpage><lpage>1114</lpage><pub-id pub-id-type="pmid">18673409</pub-id></element-citation></ref><ref id="b49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fountoulakis</surname><given-names>KN</given-names></name><name><surname>Kantartzis</surname><given-names>S</given-names></name><etal/></person-group><article-title>Peripheral thyroid dysfunction in depression</article-title><source>World J Biol Psychiatry</source><year>2006</year><volume>7</volume><fpage>131</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">16861138</pub-id></element-citation></ref><ref id="b50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carta</surname><given-names>MG</given-names></name><name><surname>Hardoy</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy</article-title><source>Clin Pract Epidemol Ment Health</source><year>2007</year><volume>3</volume><fpage>22</fpage></element-citation></ref><ref id="b51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liangpunsakul</surname><given-names>S</given-names></name><name><surname>Qi</surname><given-names>R</given-names></name><name><surname>Crabb</surname><given-names>DW</given-names></name><name><surname>Witzmann</surname><given-names>F</given-names></name></person-group><article-title>Relationship between alcohol drinking and aspartate aminotransferase:alanine aminotransferase (AST:ALT) ratio, mean corpuscular volume (MCV), gamma-glutamyl transpeptidase (GGT), and apolipoprotein A1 and B in the U.S. population</article-title><source>J Stud Alcohol Drugs</source><year>2010</year><volume>71</volume><fpage>249</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">20230722</pub-id></element-citation></ref><ref id="b52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shacham</surname><given-names>E</given-names></name><name><surname>Nurutdinova</surname><given-names>D</given-names></name><name><surname>Satyanarayana</surname><given-names>V</given-names></name><name><surname>Stamm</surname><given-names>K</given-names></name><name><surname>Overton</surname><given-names>ET</given-names></name></person-group><article-title>Routine screening for depression: identifying a challenge for successful HIV care</article-title><source>AIDS Patient Care STDS</source><year>2009</year><volume>23</volume><fpage>949</fpage><lpage>955</lpage><pub-id pub-id-type="pmid">19925308</pub-id></element-citation></ref><ref id="b53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name><surname>Landerman</surname><given-names>L</given-names></name><etal/></person-group><article-title>Uncertainty, symptoms, and quality of life in persons with chronic hepatitis C</article-title><source>Psychosomatics</source><year>2009</year><volume>50</volume><fpage>138</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">19377022</pub-id></element-citation></ref><ref id="b54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>KO</given-names></name><name><surname>Resnick</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>V</given-names></name></person-group><article-title>Depression after infection with West Nile virus</article-title><source>Emerg Infect Dis</source><year>2007</year><volume>13</volume><fpage>479</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">17552106</pub-id></element-citation></ref><ref id="b55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>AH</given-names></name><name><surname>Silberstein</surname><given-names>C</given-names></name><etal/></person-group><article-title>Epstein-Barr virus infection and depression</article-title><source>J Clin Psychiatry</source><year>1986</year><volume>47</volume><fpage>529</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">3020010</pub-id></element-citation></ref><ref id="b56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>GE</given-names></name><name><surname>Freedland</surname><given-names>KE</given-names></name><name><surname>Duntley</surname><given-names>S</given-names></name><name><surname>Carney</surname><given-names>RM</given-names></name></person-group><article-title>Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes</article-title><source>Am J Cardiol</source><year>2005</year><volume>95</volume><fpage>317</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">15670537</pub-id></element-citation></ref><ref id="b57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Wadee</surname><given-names>AA</given-names></name><name><surname>Kuschke</surname><given-names>RH</given-names></name><name><surname>O'Neill-Kerr</surname><given-names>A</given-names></name></person-group><article-title>Acute phase proteins in major depression</article-title><source>J Psychosom Res</source><year>1997</year><volume>43</volume><fpage>529</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">9394269</pub-id></element-citation></ref><ref id="b58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>BK</given-names></name><name><surname>Hickie</surname><given-names>IB</given-names></name><etal/></person-group><article-title>The relationship between fatigue, psychological and immunological variables in acute infectious illness</article-title><source>Aust N Z J Psychiatry</source><year>1998</year><volume>32</volume><fpage>180</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">9588296</pub-id></element-citation></ref><ref id="b59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Santos</surname><given-names>R</given-names></name><name><surname>Diez-Quevedo</surname><given-names>C</given-names></name><etal/></person-group><article-title>De novo depression and anxiety disorders and influence on adherence during PEGinterferon-alpha-2a and ribavirin treatment in patients with hepatitis C</article-title><source>Aliment Pharmacol Ther</source><year>2008</year><volume>27</volume><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">17988237</pub-id></element-citation></ref><ref id="b60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewhurst</surname><given-names>K</given-names></name></person-group><article-title>The neurosyphilitic psychoses today. A survey of 91 cases</article-title><source>Br J Psychiatry</source><year>1969</year><volume>115</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">5781959</pub-id></element-citation></ref><ref id="b61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega-Hernandez</surname><given-names>OD</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group><article-title>Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence?</article-title><source>Ann NYAcad Sd</source><year>2009</year><volume>1173</volume><fpage>600</fpage><lpage>609</lpage></element-citation></ref><ref id="b62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fergusson</surname><given-names>DM</given-names></name><name><surname>Boden</surname><given-names>JM</given-names></name><name><surname>Horwood</surname><given-names>LJ</given-names></name></person-group><article-title>Tests of causal links between alcohol abuse or dependence and major depression</article-title><source>Arch Gen Psychiatry</source><year>2009</year><volume>66</volume><fpage>260</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">19255375</pub-id></element-citation></ref><ref id="b63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroon</surname><given-names>LA</given-names></name></person-group><article-title>Drug interactions with smoking</article-title><source>Am J Health Syst Pharm</source><year>2007</year><volume>64</volume><fpage>1917</fpage><lpage>1921</lpage><pub-id pub-id-type="pmid">17823102</pub-id></element-citation></ref><ref id="b64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubin</surname><given-names>HJ</given-names></name></person-group><article-title>Management of emergent psychiatric symptoms during smoking cessation</article-title><source>Curr Med Res Opin</source><year>2009</year><volume>25</volume><fpage>519</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">19193000</pub-id></element-citation></ref><ref id="b65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaminer</surname><given-names>Y</given-names></name><name><surname>Connor</surname><given-names>DF</given-names></name><name><surname>Curry</surname><given-names>JF</given-names></name></person-group><article-title>Treatment of comorbid adolescent cannabis use and major depressive disorder</article-title><source><italic>Psychiatry</italic> (Edgmont)</source><year>2008</year><volume>5</volume><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">19727258</pub-id></element-citation></ref><ref id="b66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornstein</surname><given-names>SG</given-names></name><name><surname>Schneider</surname><given-names>RK</given-names></name></person-group><article-title>Clinical features of treatment-resistant depression</article-title><source>J Clin Psychiatry</source><year>2001</year><volume>62S16</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">11480880</pub-id></element-citation></ref><ref id="b67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manthey</surname><given-names>L</given-names></name><name><surname>van Veen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Correlates of (inappropriate) benzodiazepine use: the Netherlands Study of Depression and Anxiety (NESDA)</article-title><source>Br J Clin Pharmacol</source><year>2011</year><volume>71</volume><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">21219408</pub-id></element-citation></ref><ref id="b68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peles</surname><given-names>E</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Naumovsky</surname><given-names>Y</given-names></name><name><surname>Adelson</surname><given-names>M</given-names></name></person-group><article-title>Depression in methadone maintenance treatment patients: rate and risk factors</article-title><source>J Affect Disord</source><year>2001</year><volume>99</volume><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">17055063</pub-id></element-citation></ref><ref id="b69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aharonovich</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>HT</given-names></name><name><surname>Nunes</surname><given-names>EV</given-names></name></person-group><article-title>Anger and depressive states among treatment-seeking drug abusers: testing the psychopharmacological specificity hypothesis</article-title><source>Am J Addict</source><year>2001</year><volume>10</volume><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">11783747</pub-id></element-citation></ref><ref id="b70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahrke</surname><given-names>MS</given-names></name><name><surname>Yesalis</surname><given-names>CE</given-names><suffix>3rd</suffix></name><name><surname>Wright</surname><given-names>JE</given-names></name></person-group><article-title>Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update</article-title><source>Sports Med</source><year>1996</year><volume>22</volume><fpage>367</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">8969015</pub-id></element-citation></ref><ref id="b71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>CA</given-names></name></person-group><article-title>Steroids, reproductive endocrine function, and affect. A review</article-title><source>Minerva Ginecol</source><year>2009</year><volume>61</volume><fpage>541</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">19942840</pub-id></element-citation></ref><ref id="b72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sternbach</surname><given-names>H</given-names></name><name><surname>State</surname><given-names>R</given-names></name></person-group><article-title>Antibiotics: neuropsychiatric effects and psychotropic interactions</article-title><source>Harv Rev Psychiatry</source><year>1997</year><volume>5</volume><fpage>214</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">9427014</pub-id></element-citation></ref><ref id="b73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>M</given-names></name><name><surname>Engelbrecht</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Interferon alpha (IFNalpha) and psychiatric syndromes: a review</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2002</year><volume>26</volume><fpage>731</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">12188106</pub-id></element-citation></ref><ref id="b74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanner</surname><given-names>AM</given-names></name><name><surname>Wuu</surname><given-names>J</given-names></name><name><surname>Faught</surname><given-names>E</given-names></name><name><surname>Tatum</surname><given-names>WOt</given-names></name><name><surname>Fix</surname><given-names>A</given-names></name><name><surname>French</surname><given-names>JA</given-names></name></person-group><article-title>A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events</article-title><source>Epilepsy Behav</source><year>2003</year><volume>4</volume><fpage>548</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">14527497</pub-id></element-citation></ref><ref id="b75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollister</surname><given-names>LE</given-names></name></person-group><article-title>Drug-induced psychiatric disorders and their management</article-title><source>Med Toxicol</source><year>1986</year><volume>1</volume><fpage>428</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">3540520</pub-id></element-citation></ref><ref id="b76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>DA</given-names></name></person-group><article-title>Drug-induced psychiatric disorders</article-title><source>Drugs</source><year>1981</year><volume>22</volume><fpage>57</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">6114850</pub-id></element-citation></ref><ref id="b77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>JA</given-names></name></person-group><article-title>Psychiatric complications of medical drugs</article-title><source>J Fam Pract</source><year>1979</year><volume>9</volume><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">379269</pub-id></element-citation></ref><ref id="b78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitlock</surname><given-names>FA</given-names></name></person-group><article-title>Adverse psychiatric reactions to modern medication</article-title><source>Aust N Z J Psychiatry</source><year>1981</year><volume>15</volume><fpage>87</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">6116487</pub-id></element-citation></ref><ref id="b79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mithal</surname><given-names>A</given-names></name><name><surname>Wahl</surname><given-names>D</given-names></name><etal/></person-group><article-title>Global vitamin D status and determinants of hypovitaminosis D</article-title><source>Osteoporos Int</source><year>2009</year></element-citation></ref><ref id="b80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasco</surname><given-names>J</given-names></name><name><surname>Henry</surname><given-names>M</given-names></name><name><surname>Nicholson</surname><given-names>G</given-names></name><name><surname>Sanders</surname><given-names>K</given-names></name><name><surname>Kotowicz</surname><given-names>M</given-names></name></person-group><article-title>Vitamin D status of women in the Geelong Osteoporosis Study: association with diet and casual exposure to sunlight</article-title><source>Med J Aust</source><year>2001</year><volume>175</volume><fpage>401</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">11700831</pub-id></element-citation></ref><ref id="b81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Mei</surname><given-names>I</given-names></name><name><surname>Ponsonby</surname><given-names>A-L</given-names></name><etal/></person-group><article-title>The high prevalence of vitamin D insufficiency across Australian populations is only partly explained by season and latitude</article-title><source>Environ Health Perspect</source><year>2007</year><volume>115</volume><fpage>1132</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">17687438</pub-id></element-citation></ref><ref id="b82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrath</surname><given-names>J</given-names></name><name><surname>Kimlin</surname><given-names>M</given-names></name><name><surname>Saha</surname><given-names>S</given-names></name><name><surname>Eyles</surname><given-names>D</given-names></name><name><surname>Parisi</surname><given-names>A</given-names></name></person-group><article-title>Vitamin D insufficiency in south-east Queensland</article-title><source>Med J Aust</source><year>2001</year><volume>174</volume><fpage>150</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">11247622</pub-id></element-citation></ref><ref id="b83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name></person-group><article-title>Living in low-latitude regions in the United States does not prevent poor vitamin D status</article-title><source>Nutr Rev</source><year>2005</year><volume>63</volume><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">16028564</pub-id></element-citation></ref><ref id="b84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexopoulos</surname><given-names>GS</given-names></name><name><surname>Meyers</surname><given-names>BS</given-names></name><name><surname>Young</surname><given-names>RC</given-names></name><name><surname>Campbell</surname><given-names>S</given-names></name><name><surname>Silbersweig</surname><given-names>D</given-names></name><name><surname>Charlson</surname><given-names>M</given-names></name></person-group><article-title>&#x02018;Vascular depression&#x02019; hypothesis</article-title><source>Arch Gen Psychiatry</source><year>1997</year><volume>54</volume><fpage>915</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">9337771</pub-id></element-citation></ref><ref id="b85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrath</surname><given-names>J</given-names></name></person-group><article-title>Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia?</article-title><source>Schrizophr Res</source><year>1999</year><volume>40</volume><fpage>173</fpage><lpage>177</lpage></element-citation></ref><ref id="b86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milaneschi</surname><given-names>Y</given-names></name><name><surname>Shardell</surname><given-names>M</given-names></name><etal/></person-group><article-title>Serum 25-hydroxyvitamin D and depressive symptoms in older women and men</article-title><source>J Clin Endocrinol Metab</source><year>2010</year><volume>95</volume><fpage>3225</fpage><lpage>3233</lpage><pub-id pub-id-type="pmid">20444911</pub-id></element-citation></ref><ref id="b87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganji</surname><given-names>V</given-names></name><name><surname>Milone</surname><given-names>C</given-names></name><name><surname>Cody</surname><given-names>MM</given-names></name><name><surname>McCarty</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>YT</given-names></name></person-group><article-title>Serum vitamin D concentrations are related to depression in young adult US population: the Third National Health and Nutrition Examination Survey</article-title><source>Int Arch Med</source><year>2010</year><volume>3</volume><fpage>29</fpage><pub-id pub-id-type="pmid">21067618</pub-id></element-citation></ref><ref id="b88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khajehei</surname><given-names>M</given-names></name><name><surname>Abdali</surname><given-names>K</given-names></name><name><surname>Parsanezhad</surname><given-names>ME</given-names></name><name><surname>Tabatabaee</surname><given-names>HR</given-names></name></person-group><article-title>Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome</article-title><source>Int J Gynaecol Obstet</source><year>2009</year><volume>105</volume><fpage>158</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">19232611</pub-id></element-citation></ref><ref id="b89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>KM</given-names></name><name><surname>Stuart</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Annual high-dose vitamin D3 and mental well-being: randomised controlled trial</article-title><source>Br J Psychiatry</source><year>2011</year><volume>198</volume><fpage>357</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">21525520</pub-id></element-citation></ref><ref id="b90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gariballa</surname><given-names>S</given-names></name><name><surname>Forster</surname><given-names>S</given-names></name></person-group><article-title>Effects of dietary supplements on depressive symptoms in older patients: a randomised double-blind placebo-controlled trial</article-title><source>Clin Nutr</source><year>2007</year><volume>26</volume><fpage>545</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">17662509</pub-id></element-citation></ref><ref id="b91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>JG</given-names></name><name><surname>Mackinnon</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Mental health literacy, folic acid and vitamin B12, and physical activity for the prevention of depression in older adults: randomised controlled trial</article-title><source>Br J Psychiatry</source><year>2010</year><volume>197</volume><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">20592433</pub-id></element-citation></ref><ref id="b92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>SH</given-names></name><name><surname>Bedson</surname><given-names>E</given-names></name><etal/></person-group><article-title>Folate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial</article-title><source>BMC Psychiatry</source><year>2007</year><volume>7</volume><fpage>65</fpage><pub-id pub-id-type="pmid">18005429</pub-id></element-citation></ref><ref id="b93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweitzer</surname><given-names>I</given-names></name><name><surname>Tuckwell</surname><given-names>V</given-names></name><name><surname>O'Brien</surname><given-names>J</given-names></name><name><surname>Ames</surname><given-names>D</given-names></name></person-group><article-title>Is late onset depression a prodrome to dementia?</article-title><source>Int J Geriatr Psychiatry</source><year>2002</year><volume>17</volume><fpage>997</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">12404648</pub-id></element-citation></ref><ref id="b94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>SL</given-names></name><name><surname>Persad</surname><given-names>C</given-names></name></person-group><article-title>Distinguishing between depression and dementia in older persons: neuropsychological and neuropathological correlates</article-title><source>J Geriatr Psychiatry Neurol</source><year>2007</year><volume>20</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">18004006</pub-id></element-citation></ref><ref id="b95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>J</given-names></name><name><surname>Ames</surname><given-names>D</given-names></name><name><surname>Chiu</surname><given-names>E</given-names></name><name><surname>Schweitzer</surname><given-names>I</given-names></name><name><surname>Desmond</surname><given-names>P</given-names></name><name><surname>Tress</surname><given-names>B</given-names></name></person-group><article-title>Severe deep white matter lesions and outcome in elderly patients with major depressive disorder: follow up study</article-title><source>BMJ</source><year>1998</year><volume>317</volume><fpage>982</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">9765166</pub-id></element-citation></ref><ref id="b96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascade</surname><given-names>E</given-names></name><name><surname>Kalali</surname><given-names>AH</given-names></name><name><surname>Kennedy</surname><given-names>SH</given-names></name></person-group><article-title>Real-world data on SSRI antidepressant side effects</article-title><source><italic>Psychiatry</italic> (Edgmont)</source><year>2009</year><volume>6</volume><fpage>16</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">19724743</pub-id></element-citation></ref><ref id="b97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Cleeman</surname><given-names>JI</given-names></name><etal/></person-group><article-title>Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement</article-title><source>Circulation</source><year>2005</year><volume>112</volume><fpage>2735</fpage><lpage>2752</lpage><pub-id pub-id-type="pmid">16157765</pub-id></element-citation></ref><ref id="b98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heiskanen</surname><given-names>TH</given-names></name><name><surname>Niskanen</surname><given-names>LK</given-names></name><etal/></person-group><article-title>Metabolic syndrome and depression: a cross-sectional analysis</article-title><source>J Clin Psychiatry</source><year>2006</year><volume>67</volume><fpage>1422</fpage><lpage>1427</lpage><pub-id pub-id-type="pmid">17017829</pub-id></element-citation></ref><ref id="b99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>N</given-names></name><name><surname>Juckel</surname><given-names>G</given-names></name><name><surname>Assion</surname><given-names>HJ</given-names></name></person-group><article-title>Metabolic syndrome: a follow-up study of acute depressive inpatients</article-title><source>Eur Arch Psychiatry Clin Neurosci</source><volume>260</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">19399357</pub-id></element-citation></ref><ref id="b100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>T</given-names></name><name><surname>Nakao</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of the metabolic syndrome with depression and anxiety in Japanese men: a 1-year cohort study</article-title><source>Diabetes Metab Res Rev</source><year>2009</year><volume>25</volume><fpage>762</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">19839027</pub-id></element-citation></ref><ref id="b101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glassman</surname><given-names>AH</given-names></name><name><surname>Shapiro</surname><given-names>PA</given-names></name></person-group><article-title>Depression and the course of coronary artery disease</article-title><source>Am J Psychiatry</source><year>1998</year><volume>155</volume><fpage>4</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">9433332</pub-id></element-citation></ref><ref id="b102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>JB</given-names></name></person-group><article-title>Cardiac disorders and antidepressant medications</article-title><source>J Psychol</source><year>2000</year><volume>134</volume><fpage>162</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">10766108</pub-id></element-citation></ref><ref id="b103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khawaja</surname><given-names>IS</given-names></name><name><surname>Feinstein</surname><given-names>RE</given-names></name></person-group><article-title>Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants</article-title><source>Heart Dis</source><year>2003</year><volume>5</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">12713682</pub-id></element-citation></ref><ref id="b104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>S</given-names></name><name><surname>McKeon</surname><given-names>P</given-names></name><name><surname>O'Regan</surname><given-names>M</given-names></name><name><surname>O'Flaherty</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name></person-group><article-title>Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline</article-title><source>J Clin Psychopharmacol</source><year>1992</year><volume>12</volume><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">1573032</pub-id></element-citation></ref><ref id="b105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>AD</given-names></name><name><surname>Waring</surname><given-names>WS</given-names></name></person-group><article-title>Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases</article-title><source>Br J Clin Pharmacol</source><year>2007</year><volume>64</volume><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">17298480</pub-id></element-citation></ref><ref id="b106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolkowitz</surname><given-names>OM</given-names></name><name><surname>Burke</surname><given-names>H</given-names></name><name><surname>Epel</surname><given-names>ES</given-names></name><name><surname>Reus</surname><given-names>VI</given-names></name></person-group><article-title>Glucocorticoids. Mood, memory, and mechanisms</article-title><source>Ann N Y Acad Sci</source><year>2009</year><volume>1179</volume><fpage>19</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">19906230</pub-id></element-citation></ref><ref id="b107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anisman</surname><given-names>H</given-names></name><name><surname>Ravindran</surname><given-names>AV</given-names></name><name><surname>Griffiths</surname><given-names>J</given-names></name><name><surname>Merali</surname><given-names>Z</given-names></name></person-group><article-title>Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features</article-title><source>Mol Psychiatry</source><year>1999</year><volume>4</volume><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">10208451</pub-id></element-citation></ref><ref id="b108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchesi</surname><given-names>C</given-names></name><name><surname>Bertoni</surname><given-names>S</given-names></name><name><surname>Maggini</surname><given-names>C</given-names></name></person-group><article-title>Major and minor depression in pregnancy</article-title><source>Obstet Gynecol</source><year>2009</year><volume>113</volume><fpage>1292</fpage><lpage>1298</lpage><pub-id pub-id-type="pmid">19461425</pub-id></element-citation></ref><ref id="b109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name></person-group><article-title>The safety of medications for the treatment of bipolar disorder during pregnancy and the puerperium</article-title><source>Curr Drug Saf</source><year>2006</year><volume>1</volume><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">18690912</pub-id></element-citation></ref><ref id="b110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name></person-group><article-title>The pharmacology of bipolar disorder during pregnancy and breastfeeding</article-title><source>Expert Opin Drug Saf</source><year>2004</year><volume>3</volume><fpage>221</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">15155150</pub-id></element-citation></ref><ref id="b111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>KL</given-names></name><name><surname>Ellingrod</surname><given-names>VL</given-names></name></person-group><article-title>Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions</article-title><source>Pharmacotherapy</source><year>2009</year><volume>29</volume><fpage>822</fpage><lpage>831</lpage><pub-id pub-id-type="pmid">19558256</pub-id></element-citation></ref><ref id="b112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Leon</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>SC</given-names></name><name><surname>Cozza</surname><given-names>KL</given-names></name></person-group><article-title>Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19</article-title><source>Psychosomatics</source><year>2006</year><volume>47</volume><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">16384813</pub-id></element-citation></ref><ref id="b113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group><article-title>Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future</article-title><source>Trends Pharmacol Sci</source><year>2004</year><volume>25</volume><fpage>193</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">15063083</pub-id></element-citation></ref><ref id="b114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>A</given-names></name></person-group><article-title>Pharmacogenomics: the potential of genetically guided prescribing</article-title><source>Aust Fam Physician</source><year>2007</year><volume>36</volume><fpage>820</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">17925902</pub-id></element-citation></ref><ref id="b115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laje</surname><given-names>G</given-names></name><name><surname>Paddock</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genetic markers of suicidal ideation emerging during citalopram treatment of major depression</article-title><source>Am J Psychiatry</source><year>2007</year><volume>164</volume><fpage>1530</fpage><lpage>1538</lpage><pub-id pub-id-type="pmid">17898344</pub-id></element-citation></ref><ref id="b116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhi</surname><given-names>GS</given-names></name><name><surname>Lagopoulos</surname><given-names>J</given-names></name></person-group><article-title>Making sense of neuroimaging in psychiatry</article-title><source>Ada Psychiatr Scand</source><year>2008</year><volume>117</volume><fpage>100</fpage><lpage>117</lpage></element-citation></ref><ref id="b117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loo</surname><given-names>C</given-names></name><name><surname>Trollor</surname><given-names>J</given-names></name><name><surname>Alonzo</surname><given-names>A</given-names></name><name><surname>Rendina</surname><given-names>N</given-names></name><name><surname>Kavess</surname><given-names>R</given-names></name></person-group><article-title>Mental health legislation and psychiatric treatments in NSW: electroconvulsive therapy and deep brain stimulation</article-title><source>Australas Psychiatry</source><year>2010</year><volume>18</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">20863180</pub-id></element-citation></ref><ref id="b118"><label>118</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tiller</surname><given-names>JWG</given-names></name><name><surname>Lyndon</surname><given-names>RW</given-names></name></person-group><source>Electroconvulsive therapy: an Australasian guide</source><year>2003</year><publisher-loc>Fitzroy, VIC</publisher-loc><publisher-name>Australian Postgraduate Medicine</publisher-name></element-citation></ref><ref id="b119"><label>119</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>McDermott</surname><given-names>B</given-names></name><name><surname>Baigent</surname><given-names>M</given-names></name><etal/></person-group><article-title>beyondblue Expert Working Committee (2010) Clinical practice guidelines: Depression in adolescents and young adults</article-title><year>2010</year><publisher-loc>Melbourne</publisher-loc><publisher-name>beyondblue: the national depression initiative</publisher-name><comment>Available at URL: <ext-link ext-link-type="uri" xlink:href="http://www.beyondblue.org.au/index.aspx?link_id=6.1247&#x00026;tmp=FileDownload&#x00026;fid=1625">http://www.beyondblue.org.au/index.aspx?link_id=6.1247&#x00026;tmp=FileDownload&#x00026;fid=1625</ext-link></comment></element-citation></ref><ref id="b120"><label>120</label><element-citation publication-type="book"><collab>The Australian Government Department of Health and Ageing</collab><article-title>The Living Is For Everyone (LIFE) framework</article-title><year>2007</year><publisher-loc>Canberra</publisher-loc><publisher-name>Commonwealth of Australia</publisher-name><comment>Available at URL: <ext-link ext-link-type="uri" xlink:href="http://www.livingisforeveryone.com.au/IgnitionSuite/uploads/docs/LIFE_framework-web.pdf">http://www.livingisforeveryone.com.au/IgnitionSuite/uploads/docs/LIFE_framework-web.pdf</ext-link></comment></element-citation></ref><ref id="b121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risselada</surname><given-names>AJ</given-names></name><name><surname>Mulder</surname><given-names>H</given-names></name><name><surname>Heerdink</surname><given-names>ER</given-names></name><name><surname>Grube</surname><given-names>AM</given-names></name><name><surname>Wilmink</surname><given-names>FW</given-names></name><name><surname>Egberts</surname><given-names>TC</given-names></name></person-group><article-title>The association between serotonin 2C receptor polymorphisms and weight gain and eating behavior in patients using mirtazapine: a prospective follow-up study</article-title><source>J Clin Psychopharmacol</source><volume>30</volume><fpage>207</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">20520301</pub-id></element-citation></ref><ref id="b122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernstrom</surname><given-names>MH</given-names></name><name><surname>Kupfer</surname><given-names>DJ</given-names></name></person-group><article-title>Antidepressant-induced weight gain: a comparison study of four medications</article-title><source>Psychiatry Res</source><year>1988</year><volume>26</volume><fpage>265</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">2975806</pub-id></element-citation></ref><ref id="b123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hainer</surname><given-names>V</given-names></name><name><surname>Kabrnova</surname><given-names>K</given-names></name><name><surname>Aldhoon</surname><given-names>B</given-names></name><name><surname>Kunesova</surname><given-names>M</given-names></name><name><surname>Wagenknecht</surname><given-names>M</given-names></name></person-group><article-title>Serotonin and norepinephrine reuptake inhibition and eating behavior</article-title><source>Ann N Y Acad Sci</source><year>2006</year><volume>1083</volume><fpage>252</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">17148744</pub-id></element-citation></ref><ref id="b124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ormerod</surname><given-names>S</given-names></name><name><surname>McDowell</surname><given-names>SE</given-names></name><name><surname>Coleman</surname><given-names>JJ</given-names></name><name><surname>Ferner</surname><given-names>RE</given-names></name></person-group><article-title>Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis</article-title><source>Drug Saf</source><year>2008</year><volume>31</volume><fpage>597</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">18558793</pub-id></element-citation></ref><ref id="b125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>M</given-names></name></person-group><article-title>Weight gain and antidepressants</article-title><source>J Clin Psychiatry</source><year>2000</year><volume>61S11</volume><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">10926053</pub-id></element-citation></ref><ref id="b126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>HJ</given-names></name><name><surname>Jung</surname><given-names>YE</given-names></name><name><surname>Woo</surname><given-names>YS</given-names></name><name><surname>Jun</surname><given-names>TY</given-names></name><name><surname>Chae</surname><given-names>JH</given-names></name><name><surname>Bahk</surname><given-names>WM</given-names></name></person-group><article-title>Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting</article-title><source>Hum Psychopharmacol</source><year>2009</year><volume>24</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">19156709</pub-id></element-citation></ref><ref id="b127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reilly</surname><given-names>JG</given-names></name><name><surname>Ayis</surname><given-names>SA</given-names></name><name><surname>Ferrier</surname><given-names>IN</given-names></name><name><surname>Jones</surname><given-names>SJ</given-names></name><name><surname>Thomas</surname><given-names>SH</given-names></name></person-group><article-title>QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1048</fpage><lpage>1052</lpage><pub-id pub-id-type="pmid">10744090</pub-id></element-citation></ref><ref id="b128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>YG</given-names></name><name><surname>Camm</surname><given-names>AJ</given-names></name></person-group><article-title>Drug induced QT prolongation and torsades de pointes</article-title><source>Heart</source><year>2003</year><volume>89</volume><fpage>1363</fpage><lpage>1372</lpage><pub-id pub-id-type="pmid">14594906</pub-id></element-citation></ref><ref id="b129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamene</surname><given-names>A</given-names></name><name><surname>Sattiraju</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Benditt</surname><given-names>DG</given-names></name></person-group><article-title>Brugada-like electrocardiography pattern induced by severe hyponatraemia</article-title><source>Europace</source><year>2010</year><volume>12</volume><fpage>905</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">20185483</pub-id></element-citation></ref><ref id="b130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darpo</surname><given-names>B</given-names></name></person-group><article-title>Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes</article-title><source>Eur Heart J Suppl</source><year>2001</year><volume>3</volume><fpage>K70</fpage><lpage>K80</lpage></element-citation></ref><ref id="b131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouleau</surname><given-names>F</given-names></name><name><surname>Asfar</surname><given-names>P</given-names></name><etal/></person-group><article-title>Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome</article-title><source>J Cardiovasc Electrophysiol</source><year>2001</year><volume>12</volume><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">11204086</pub-id></element-citation></ref><ref id="b132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Civalier</surname><given-names>KA</given-names></name><name><surname>Krahn</surname><given-names>LE</given-names></name><name><surname>Agrwal</surname><given-names>N</given-names></name></person-group><article-title>Repeated episodes of neutropenia triggered by mirtazapine</article-title><source>Psychosomatics</source><year>2009</year><volume>50</volume><fpage>299</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">19567774</pub-id></element-citation></ref><ref id="b133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersohn</surname><given-names>F</given-names></name><name><surname>Konzen</surname><given-names>C</given-names></name><name><surname>Bronder</surname><given-names>E</given-names></name><name><surname>Klimpel</surname><given-names>A</given-names></name><name><surname>Garbe</surname><given-names>E</given-names></name></person-group><article-title>Citalopram-induced bleeding due to severe thrombocytopenia</article-title><source>Psychosomatics</source><year>2009</year><volume>50</volume><fpage>297</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">19567773</pub-id></element-citation></ref><ref id="b134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucena</surname><given-names>MI</given-names></name><name><surname>Carvajal</surname><given-names>A</given-names></name><name><surname>Andrade</surname><given-names>RJ</given-names></name><name><surname>Velasco</surname><given-names>A</given-names></name></person-group><article-title>Antidepressant-induced hepatotoxicity</article-title><source>Expert Opin Drug Saf</source><year>2003</year><volume>2</volume><fpage>249</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">12904104</pub-id></element-citation></ref><ref id="b135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azaz-Livshits</surname><given-names>T</given-names></name><name><surname>Hershko</surname><given-names>A</given-names></name><name><surname>Ben-Chetrit</surname><given-names>E</given-names></name></person-group><article-title>Paroxetine associated hepatotoxicity: a report of 3 cases and a review of the literature</article-title><source>Pharmacopsychiatry</source><year>2002</year><volume>35</volume><fpage>112</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">12107856</pub-id></element-citation></ref><ref id="b136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pompili</surname><given-names>M</given-names></name><name><surname>Tittoto</surname><given-names>P</given-names></name><name><surname>Masciana</surname><given-names>R</given-names></name><name><surname>Gasbarrini</surname><given-names>G</given-names></name><name><surname>Rapaccini</surname><given-names>GL</given-names></name></person-group><article-title>Acute hepatitis associated with use of paroxetine</article-title><source>Intern Emerg Med</source><year>2008</year><volume>3</volume><fpage>275</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">18265937</pub-id></element-citation></ref><ref id="b137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colakoglu</surname><given-names>O</given-names></name><name><surname>Tankurt</surname><given-names>E</given-names></name><etal/></person-group><article-title>Toxic hepatitis associated with paroxetine</article-title><source>Int J Clin Pract</source><year>2005</year><volume>59</volume><fpage>861</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">15963219</pub-id></element-citation></ref><ref id="b138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabak</surname><given-names>F</given-names></name><name><surname>Gunduz</surname><given-names>F</given-names></name><name><surname>Tahan</surname><given-names>V</given-names></name><name><surname>Tabak</surname><given-names>O</given-names></name><name><surname>Ozaras</surname><given-names>R</given-names></name></person-group><article-title>Sertraline hepatotoxicity: report of a case and review of the literature</article-title><source>Dig Dis Sci</source><year>2009</year><volume>54</volume><fpage>1589</fpage><lpage>1591</lpage><pub-id pub-id-type="pmid">18958618</pub-id></element-citation></ref><ref id="b139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persky</surname><given-names>S</given-names></name><name><surname>Reinus</surname><given-names>JF</given-names></name></person-group><article-title>Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity</article-title><source>Dig Dis Sci</source><year>2003</year><volume>48</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">12772794</pub-id></element-citation></ref><ref id="b140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedenberg</surname><given-names>FK</given-names></name><name><surname>Rothstein</surname><given-names>KD</given-names></name></person-group><article-title>Hepatitis secondary to fluoxetine treatment</article-title><source>Am J Psychiatry</source><year>1996</year><volume>153</volume><fpage>580</fpage><pub-id pub-id-type="pmid">8599417</pub-id></element-citation></ref><ref id="b141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Benson</surname><given-names>MA</given-names></name><name><surname>Talbot</surname><given-names>TJ</given-names></name><name><surname>Devadas</surname><given-names>G</given-names></name><name><surname>Swanson</surname><given-names>HJ</given-names></name><name><surname>Olson</surname><given-names>JL</given-names></name><name><surname>Kirchner</surname><given-names>JP</given-names></name></person-group><article-title>Acute hepatitis due to fluoxetine therapy</article-title><source>Mayo Clin Proc</source><year>1999</year><volume>74</volume><fpage>692</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">10405699</pub-id></element-citation></ref><ref id="b142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otani</surname><given-names>K</given-names></name><name><surname>Kaneko</surname><given-names>S</given-names></name><name><surname>Tasaki</surname><given-names>H</given-names></name><name><surname>Fukushima</surname><given-names>Y</given-names></name></person-group><article-title>Hepatic injury caused by mianserin</article-title><source>BMJ</source><year>1989</year><volume>299</volume><fpage>519</fpage><pub-id pub-id-type="pmid">2507056</pub-id></element-citation></ref><ref id="b143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>CK</given-names></name><name><surname>Yuen</surname><given-names>MF</given-names></name><name><surname>Wong</surname><given-names>WM</given-names></name><name><surname>Lam</surname><given-names>SK</given-names></name><name><surname>Lai</surname><given-names>CL</given-names></name></person-group><article-title>Mirtazapine-induced hepatotoxicity</article-title><source>J Clin Gastroenterol</source><year>2002</year><volume>35</volume><fpage>270</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">12192206</pub-id></element-citation></ref><ref id="b144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adetunji</surname><given-names>B</given-names></name><name><surname>Basil</surname><given-names>B</given-names></name><name><surname>Mathews</surname><given-names>M</given-names></name><name><surname>Osinowo</surname><given-names>T</given-names></name></person-group><article-title>Mirtazapine-associated dose-dependent and asymptomatic elevation of hepatic enzymes</article-title><source>Ann Pharmacother</source><year>2007</year><volume>41</volume><fpage>359</fpage><pub-id pub-id-type="pmid">17244643</pub-id></element-citation></ref><ref id="b145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humayun</surname><given-names>F</given-names></name><name><surname>Shehab</surname><given-names>TM</given-names></name><name><surname>Tworek</surname><given-names>JA</given-names></name><name><surname>Fontana</surname><given-names>RJ</given-names></name></person-group><article-title>A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report</article-title><source>J Med Case Reports</source><year>2007</year><volume>1</volume><fpage>88</fpage><pub-id pub-id-type="pmid">17877816</pub-id></element-citation></ref><ref id="b146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Detry</surname><given-names>O</given-names></name><name><surname>Delwaide</surname><given-names>J</given-names></name><etal/></person-group><article-title>Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report</article-title><source>Transplant Proc</source><year>2009</year><volume>41</volume><fpage>3435</fpage><lpage>3436</lpage><pub-id pub-id-type="pmid">19857765</pub-id></element-citation></ref><ref id="b147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hull</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Bendall</surname><given-names>M</given-names></name></person-group><article-title>Fatal hepatic necrosis associated with trazodone and neuroleptic drugs</article-title><source>BMJ</source><year>1994</year><volume>309</volume><lpage>378</lpage></element-citation></ref><ref id="b148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mclntyre</surname><given-names>RS</given-names></name><name><surname>Panjwani</surname><given-names>ZD</given-names></name><etal/></person-group><article-title>The hepatic safety profile of duloxetine: a review</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2008</year><volume>4</volume><fpage>281</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">18363543</pub-id></element-citation></ref><ref id="b149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>RT</given-names></name></person-group><article-title>Agomelatine: a novel pharmacological approach to treating depression</article-title><source><italic>Drugs Today</italic> (Bare)</source><year>2009</year><volume>45</volume><fpage>599</fpage><lpage>608</lpage></element-citation></ref><ref id="b150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Santy</surname><given-names>KP</given-names></name><name><surname>Amabile</surname><given-names>CM</given-names></name></person-group><article-title>Antidepressant-induced liver injury</article-title><source>Ann Pharmacother</source><year>2007</year><volume>41</volume><fpage>1201</fpage><lpage>1211</lpage><pub-id pub-id-type="pmid">17609231</pub-id></element-citation></ref><ref id="b151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostrubsky</surname><given-names>SE</given-names></name><name><surname>Strom</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone</article-title><source>Toxicol Sci</source><year>2006</year><volume>90</volume><fpage>451</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">16410371</pub-id></element-citation></ref><ref id="b152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAllister-Williams</surname><given-names>RH</given-names></name><name><surname>Baldwin</surname><given-names>DS</given-names></name><name><surname>Haddad</surname><given-names>PM</given-names></name><name><surname>Bazire</surname><given-names>S</given-names></name></person-group><article-title>The use of antidepressants in clinical practice: focus on agomelatine</article-title><source>Hum Psychopharmacol</source><volume>25</volume><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">20196187</pub-id></element-citation></ref><ref id="b153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WM</given-names></name></person-group><article-title>Drug-induced hepatotoxicity</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>474</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">12890847</pub-id></element-citation></ref><ref id="b154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twardowschy</surname><given-names>CA</given-names></name><name><surname>Bertolucci</surname><given-names>CB</given-names></name><name><surname>Gracia</surname><given-names>Cde M</given-names></name><name><surname>Brandao</surname><given-names>MA</given-names></name></person-group><article-title>Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report</article-title><source>Arq Neuropsiquiatr</source><year>2006</year><volume>64</volume><fpage>142</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">16622573</pub-id></element-citation></ref><ref id="b155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>TJ</given-names></name><name><surname>Begg</surname><given-names>EJ</given-names></name><name><surname>Winter</surname><given-names>AC</given-names></name><name><surname>Sainsbury</surname><given-names>R</given-names></name></person-group><article-title>Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people</article-title><source>Br J Clin Pharmacol</source><year>1999</year><volume>47</volume><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">10190657</pub-id></element-citation></ref><ref id="b156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchner</surname><given-names>V</given-names></name><name><surname>Silver</surname><given-names>LE</given-names></name><name><surname>Kelly</surname><given-names>CA</given-names></name></person-group><article-title>Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly</article-title><source>J Psychopharmacol</source><year>1998</year><volume>12</volume><fpage>396</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">10065915</pub-id></element-citation></ref><ref id="b157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>BA</given-names></name><name><surname>Mittmann</surname><given-names>N</given-names></name><name><surname>Knowles</surname><given-names>SR</given-names></name><name><surname>Shear</surname><given-names>NH</given-names></name></person-group><article-title>Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports</article-title><source>Can Med Ass J</source><year>1996</year><volume>155</volume><fpage>519</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">8804257</pub-id></element-citation></ref><ref id="b158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barclay</surname><given-names>TS</given-names></name><name><surname>Lee</surname><given-names>AJ</given-names></name></person-group><article-title>Citalopram-associated SIADH</article-title><source>Ann Pharmacother</source><year>2002</year><volume>36</volume><fpage>1558</fpage><lpage>1563</lpage><pub-id pub-id-type="pmid">12243606</pub-id></element-citation></ref><ref id="b159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nirmalani</surname><given-names>A</given-names></name><name><surname>Stock</surname><given-names>SL</given-names></name><name><surname>Catalano</surname><given-names>G</given-names></name></person-group><article-title>Syndrome of inappropriate antidiuretic hormone associated with escitalopram therapy</article-title><source>CNS Spectr</source><year>2006</year><volume>11</volume><fpage>429</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">16816780</pub-id></element-citation></ref><ref id="b160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stovall</surname><given-names>R</given-names></name><name><surname>Brahm</surname><given-names>NC</given-names></name><name><surname>Crosby</surname><given-names>KM</given-names></name></person-group><article-title>Recurrent episodes of serotonin-reuptake inhibitor-mediated hyponatremia in an elderly patient</article-title><source>Consult Pharm</source><year>2009</year><volume>24</volume><fpage>765</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">20017411</pub-id></element-citation></ref><ref id="b161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bavbek</surname><given-names>N</given-names></name><name><surname>Kargili</surname><given-names>A</given-names></name><name><surname>Akcay</surname><given-names>A</given-names></name><name><surname>Kaya</surname><given-names>A</given-names></name></person-group><article-title>Recurrent hyponatremia associated with citalopram and mirtazapine</article-title><source>Am J Kidney Dis</source><year>2006</year><volume>48</volume><fpage>e61</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">16997047</pub-id></element-citation></ref><ref id="b162"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koelkebeck</surname><given-names>K</given-names></name><name><surname>Domschke</surname><given-names>K</given-names></name><name><surname>Zwanzger</surname><given-names>P</given-names></name><name><surname>Hetzel</surname><given-names>G</given-names></name><name><surname>Lang</surname><given-names>D</given-names></name><name><surname>Arolt</surname><given-names>V</given-names></name></person-group><article-title>A case of non-SIADH-induced hyponatremia in depression after treatment with reboxetine</article-title><source>World J Biol Psychiatry</source><year>2009</year><volume>10</volume><fpage>609</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">17965988</pub-id></element-citation></ref><ref id="b163"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosner</surname><given-names>MH</given-names></name></person-group><article-title>Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors</article-title><source>Am J Med Sci</source><year>2004</year><volume>327</volume><fpage>109</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">14770031</pub-id></element-citation></ref><ref id="b164"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>BR</given-names></name><name><surname>Fenn</surname><given-names>HH</given-names></name><name><surname>Ketter</surname><given-names>TA</given-names></name></person-group><article-title>Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin</article-title><source>Expert Opin Drug Saf</source><year>2007</year><volume>6</volume><fpage>133</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">17367259</pub-id></element-citation></ref><ref id="b165"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battaglino</surname><given-names>R</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Spate</surname><given-names>U</given-names></name><name><surname>Ersoy</surname><given-names>U</given-names></name><name><surname>Joe</surname><given-names>M</given-names></name><name><surname>Sedaghat</surname><given-names>L</given-names></name><name><surname>Stashenko</surname><given-names>P</given-names></name></person-group><article-title>Serotonin regulates osteoclast differentiation through its transporter</article-title><source>J Bone Miner Res</source><year>2004</year><volume>19</volume><fpage>1420</fpage><lpage>1431</lpage><pub-id pub-id-type="pmid">15312242</pub-id></element-citation></ref><ref id="b166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>LJ</given-names></name><name><surname>Henry</surname><given-names>MJ</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Jacka</surname><given-names>FN</given-names></name><name><surname>Kotowicz</surname><given-names>MA</given-names></name><name><surname>Nicholson</surname><given-names>GC</given-names></name><name><surname>Pasco</surname><given-names>JA</given-names></name></person-group><article-title>Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression</article-title><source>Int Clin Psychopharmacol</source><year>2008</year><volume>23</volume><fpage>84</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">18301122</pub-id></element-citation></ref><ref id="b167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolton</surname><given-names>JM</given-names></name><name><surname>Metge</surname><given-names>C</given-names></name><name><surname>Lix</surname><given-names>L</given-names></name><name><surname>Prior</surname><given-names>H</given-names></name><name><surname>Sareen</surname><given-names>J</given-names></name><name><surname>Leslie</surname><given-names>WD</given-names></name></person-group><article-title>Fracture risk from psychotropic medications: a population-based analysis</article-title><source>J Clin Psychopharmacol</source><year>2008</year><volume>28</volume><fpage>384</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">18626264</pub-id></element-citation></ref><ref id="b168"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziere</surname><given-names>G</given-names></name><name><surname>Dieleman</surname><given-names>JP</given-names></name><name><surname>van der Cammen</surname><given-names>TJ</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Pols</surname><given-names>HA</given-names></name><name><surname>Strieker</surname><given-names>BH</given-names></name></person-group><article-title>Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures</article-title><source>J Clin Psychopharmacol</source><year>2008</year><volume>28</volume><fpage>411</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">18626268</pub-id></element-citation></ref><ref id="b169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Hodge</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>L</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Nicholson</surname><given-names>G</given-names></name></person-group><article-title>The effect of SSRIs on osteoclast formation and functioning. Poster presented at the 26th Collegium Internationale Neuro-Psychopharmacologicum Congress, Munich, 13-17 July 2008</article-title><source>Int J Neuropsychopharmacol</source><year>2008</year><volume>11</volume><fpage>130</fpage></element-citation></ref><ref id="b170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemeryck</surname><given-names>A</given-names></name><name><surname>Belpaire</surname><given-names>FM</given-names></name></person-group><article-title>Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update</article-title><source>Curr Drug Metab</source><year>2002</year><volume>3</volume><fpage>13</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">11876575</pub-id></element-citation></ref><ref id="b171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Harten</surname><given-names>J</given-names></name></person-group><article-title>Overview of the pharmacokinetics of fluvoxamine</article-title><source>Clin Pharmacokinet</source><year>1995</year><volume>29</volume><fpage>S1</fpage><lpage>9</lpage></element-citation></ref><ref id="b172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandrioli</surname><given-names>R</given-names></name><name><surname>Forti</surname><given-names>GC</given-names></name><name><surname>Raggi</surname><given-names>MA</given-names></name></person-group><article-title>Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450</article-title><source>Curr Drug Metab</source><year>2006</year><volume>7</volume><fpage>127</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">16472103</pub-id></element-citation></ref><ref id="b173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spina</surname><given-names>E</given-names></name><name><surname>Santoro</surname><given-names>V</given-names></name><name><surname>D'Arrigo</surname><given-names>C</given-names></name></person-group><article-title>Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update</article-title><source>Clin Ther</source><year>2008</year><volume>30</volume><fpage>1206</fpage><lpage>1227</lpage><pub-id pub-id-type="pmid">18691982</pub-id></element-citation></ref></ref-list></back></article>